nct_id,Title,Conditions,Phases,Enrollment,DurationWeeks,Arms,DrugClass,Comparator,Masking,Allocation,InterventionModel,SponsorType,Region,PrimaryEndpoint,BaselineHbA1c,HbA1c_SD,EffectSize_HbA1c,PValue_HbA1c,Study Status,Study Results,label_reason,success_label_basic
NCT18032585,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,11,2,Other,Placebo,Double,Randomized,Parallel,Industry,North America,Weight,8.87,1.15,,,Completed,Has Results,Not met / not primary / not significant,0
NCT79656043,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,13,3,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Industry,Europe,CGM TIR,8.64,1.29,-0.148,0.44264340440375505,Completed,Has Results,Not met / not primary / not significant,0
NCT49499059,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,19,3,TZD,StandardOfCare,Single,Randomized,Parallel,Industry,North America,FPG change,8.85,1.09,-0.948,6.771753080503373e-08,Terminated,Has Results,Not met / not primary / not significant,0
NCT48971370,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,9,3,GLP-1RA,Active,Open Label,Randomized,Parallel,Academic,Other,HbA1c change,8.88,1.21,-1.022,2.680640770580389e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT87273811,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,15,3,Other,Placebo,Double,Randomized,Single Group,Industry,Multi-Region,FPG change,9.45,0.85,-0.632,5.043239107327402e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT17735107,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,23,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.38,1.74,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT72763121,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,17,6,SGLT2i,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,8.51,1.03,-0.658,0.00015596489742086828,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18475961,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,104,23,4,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Europe,HbA1c change,9.05,1.15,-1.149,6.019629239517599e-13,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57383107,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,23,3,NovelSmallMolecule,Active,Open Label,Randomized,Parallel,Industry,North America,CGM TIR,8.06,1.24,-0.276,0.20856728261080726,Completed,Has Results,Not met / not primary / not significant,0
NCT97806010,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,47,16,3,SGLT2i,Active,Double,Randomized,Parallel,Industry,North America,CGM TIR,7.47,1.0,-0.392,0.05653416704150904,Completed,Has Results,Not met / not primary / not significant,0
NCT76217712,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,144,4,2,Other,Placebo,Double,Non-Randomized,Single Group,Industry,North America,Composite,8.75,1.1,-0.252,0.05214858703190295,Completed,Has Results,Not met / not primary / not significant,0
NCT78502572,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,9,3,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,Composite,8.26,1.1,-1.001,8.248057792314967e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT74572954,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,21,2,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Asia,Weight,7.55,0.87,-1.001,2.0953350166053042e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT80745786,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,7,3,GLP-1RA,StandardOfCare,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.75,1.21,-1.214,2.9569274917484734e-08,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56190391,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,14,4,GLP-1RA,Active,Open Label,Non-Randomized,Crossover,Industry,North America,Weight,9.4,0.69,-0.768,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT21530226,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,185,18,4,TZD,Placebo,Double,Non-Randomized,Parallel,Industry,Asia,CGM TIR,7.26,1.54,-0.443,0.005558914363643752,Completed,Has Results,Not met / not primary / not significant,0
NCT85577339,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,25,5,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,Weight,9.12,1.3,-0.841,2.9810775629135478e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT50534733,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,13,3,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,North America,HbA1c change,6.62,1.26,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55031671,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,161,12,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.12,0.67,-0.46,5.648409517888808e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT43371821,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,44,16,3,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,North America,Weight,9.69,0.9,-0.949,8.053769717797366e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT26429467,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,241,18,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.17,1.45,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93408848,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,299,15,4,Other,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.46,2.0,-0.453,0.0055936219710485124,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80341070,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,30,22,4,NovelSmallMolecule,Active,Double,Randomized,Single Group,Other,Multi-Region,HbA1c change,8.93,1.4,-1.497,3.39022185849025e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67947860,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,11,3,NovelSmallMolecule,Placebo,Single,Randomized,Parallel,Academic,Europe,HbA1c change,7.2,1.36,-0.227,0.25068324355921934,Completed,Has Results,Not met / not primary / not significant,0
NCT46217292,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,17,2,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.45,1.23,-0.788,0.00012235229140200587,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84048544,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,19,4,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,Composite,8.44,0.89,-0.987,1.6497914145929826e-13,Completed,Has Results,Not met / not primary / not significant,0
NCT59088620,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,14,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,Weight,9.7,1.35,-1.36,1.0815504047911872e-10,Completed,Has Results,Not met / not primary / not significant,0
NCT49907277,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,143,21,4,GLP-1RA,Placebo,Triple,Randomized,Crossover,Academic,North America,Weight,7.53,0.82,-1.177,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT50541359,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,17,2,Insulin,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.13,0.8,-1.559,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30451484,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,21,4,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Industry,Europe,HbA1c change,7.75,0.78,-0.799,4.369306250140426e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18292232,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,17,2,TZD,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.68,1.34,-0.755,0.00013991774506916244,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59912630,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,125,18,2,NovelSmallMolecule,StandardOfCare,Single,Randomized,Parallel,Industry,North America,HbA1c change,9.19,1.09,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT15743552,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,12,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.42,1.13,-1.162,2.712922209102686e-08,Recruiting,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT87246215,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,47,12,3,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Government,Europe,CGM TIR,8.01,1.1,-0.654,0.003818752513177981,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT84486804,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,244,23,5,SGLT2i,Placebo,Triple,Randomized,Parallel,Other,North America,Composite,8.04,0.82,-1.07,0.0,Recruiting,Has Results,Not met / not primary / not significant,0
NCT34908372,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,20,6,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,8.01,0.93,-0.733,1.4668135575046648e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT66849795,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,10,5,NovelSmallMolecule,Placebo,Open Label,Randomized,Crossover,Industry,Asia,HbA1c change,8.07,0.94,-0.518,0.00017239748623809614,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24870616,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,17,3,Other,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.51,0.75,-0.302,0.009467023974096156,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78227895,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,127,4,4,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.22,0.97,-0.663,5.733272623320573e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT73047066,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,221,13,6,GLP-1RA,StandardOfCare,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.15,0.83,-0.742,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT41907336,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,22,3,TZD,DoseComparison,Single,Randomized,Single Group,Industry,Multi-Region,HbA1c change,7.87,1.24,-1.207,6.661338147750939e-15,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT16112800,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,50,15,3,GLP-1RA,Placebo,Triple,Randomized,Parallel,Government,Europe,HbA1c change,8.51,1.27,-1.328,1.5469375336252256e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97362821,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,17,4,Other,Placebo,Open Label,Randomized,Parallel,Other,North America,HbA1c change,8.57,0.78,-0.171,0.2576299727983933,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT50111873,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,4,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,North America,Weight,8.01,1.03,-0.79,7.003839886943197e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT90380900,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,14,4,GLP-1RA,Active,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.3,1.56,-0.957,4.917957238403936e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71012710,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,46,18,2,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.91,0.85,-1.2,1.6583068251918576e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80054513,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,144,19,3,SGLT2i,StandardOfCare,Double,Non-Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.88,1.21,-0.805,1.5355478999445893e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78390948,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,22,5,Other,StandardOfCare,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,7.66,1.13,-0.607,0.0028978241667665383,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT27517483,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,195,15,2,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,HbA1c change,7.76,1.37,-0.518,0.00019613242415250642,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42751542,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,226,15,4,NovelSmallMolecule,Placebo,Open Label,Randomized,Single Group,Industry,Europe,CGM TIR,7.66,1.17,-0.278,0.011810296695378919,Completed,Has Results,Not met / not primary / not significant,0
NCT52004889,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,8,3,TZD,DoseComparison,Open Label,Randomized,Parallel,Academic,North America,Weight,9.14,0.99,-0.792,1.0094963365236964e-07,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT54801238,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,121,15,2,Insulin,Placebo,Triple,Randomized,Parallel,Industry,Asia,FPG change,8.12,1.12,-1.151,1.1102230246251565e-15,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT13942338,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,8,3,GLP-1RA,Placebo,Single,Randomized,Single Group,Industry,Asia,HbA1c change,8.57,1.12,-1.763,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59191254,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,5,2,Other,Placebo,Double,Randomized,Single Group,Industry,North America,HbA1c change,9.8,1.08,,,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT23886054,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,9,3,SGLT2i,DoseComparison,Open Label,Randomized,Parallel,Other,Multi-Region,HbA1c change,8.39,0.77,-0.592,1.182565828372617e-06,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76903830,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,25,4,Insulin,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.89,1.41,-1.417,2.8883016311986864e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71474405,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,14,3,NovelSmallMolecule,StandardOfCare,Triple,Randomized,Parallel,Industry,North America,Weight,8.76,1.37,-0.399,0.05443073017798916,Completed,Has Results,Not met / not primary / not significant,0
NCT93027504,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,17,4,TZD,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,7.99,0.84,-0.884,2.02938776894257e-11,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT77028593,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,13,3,Other,DoseComparison,Triple,Randomized,Parallel,Academic,Multi-Region,HbA1c change,9.14,1.02,-1.114,1.006972283335017e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42997838,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,153,5,2,GLP-1RA,Placebo,Single,Non-Randomized,Parallel,Other,Multi-Region,HbA1c change,7.81,1.04,-0.645,6.388214834895933e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97075874,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,22,3,Insulin,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,9.34,0.81,-1.287,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT46976531,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,217,4,2,DPP-4i,DoseComparison,Double,Randomized,Parallel,Other,Other,Weight,7.99,0.63,-0.592,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT39324281,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,13,3,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.07,0.93,-0.748,2.5749866734203763e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT91498217,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,206,16,2,GLP-1RA,Placebo,Single,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.64,1.01,,,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT43341373,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,17,3,GLP-1RA,Active,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.75,0.74,-0.662,5.06328640792475e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT16870886,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,99,12,3,SGLT2i,Placebo,Double,Randomized,Crossover,Industry,Europe,CGM TIR,8.1,1.14,,,Completed,Has Results,Not met / not primary / not significant,0
NCT52260022,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,5,4,SGLT2i,Placebo,Double,Randomized,Single Group,Academic,Multi-Region,HbA1c change,6.7,1.39,-0.389,0.07652847233766313,Completed,Has Results,Not met / not primary / not significant,0
NCT81611196,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,11,2,DPP-4i,Placebo,Triple,Randomized,Parallel,Industry,Asia,FPG change,8.24,1.31,-0.871,1.4723107116809686e-05,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT27052422,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,143,12,4,TZD,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.04,1.07,-0.643,3.597113524822504e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51664650,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,195,11,4,TZD,StandardOfCare,Single,Randomized,Parallel,Academic,North America,HbA1c change,8.95,0.64,-1.111,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21692935,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,170,22,5,DPP-4i,Active,Open Label,Randomized,Parallel,Other,Multi-Region,Weight,8.7,1.28,-0.369,0.00784934442694074,Completed,Has Results,Not met / not primary / not significant,0
NCT71783038,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,9,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Other,HbA1c change,7.9,1.14,-0.574,0.0011458547176023126,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT52813442,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,18,3,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Europe,HbA1c change,8.08,1.21,-1.003,9.8009955706857e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT39717669,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,17,2,TZD,Placebo,Double,Randomized,Parallel,Academic,Other,HbA1c change,8.24,1.58,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30421841,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,22,5,SGLT2i,Active,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,9.44,0.89,-0.562,0.00037929045282425466,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT60804989,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,59,15,4,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Government,North America,HbA1c change,7.82,0.6,-0.885,1.1102230246251565e-15,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70283258,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,21,2,DPP-4i,DoseComparison,Single,Randomized,Parallel,Industry,North America,CGM TIR,7.9,0.84,-0.89,9.679923529404277e-12,Completed,Has Results,Not met / not primary / not significant,0
NCT94627547,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,111,15,2,DPP-4i,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.61,1.22,-0.632,0.00011734960747955547,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49343672,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,42,19,4,SGLT2i,Placebo,Single,Non-Randomized,Single Group,Industry,Asia,HbA1c change,7.36,1.11,-0.654,0.006775429641429631,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24461934,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,7,2,Insulin,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.61,0.8,-1.239,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84941036,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,197,4,3,Insulin,Active,Double,Randomized,Parallel,Industry,Asia,FPG change,8.54,0.75,-1.034,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT66678786,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,165,18,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.3,1.01,-0.908,3.3306690738754696e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT73023858,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,19,2,TZD,Active,Double,Non-Randomized,Parallel,Government,Europe,HbA1c change,9.13,0.79,-0.761,2.6980999656700533e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18750396,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,19,3,TZD,Active,Double,Randomized,Parallel,Other,Multi-Region,HbA1c change,10.08,1.23,-1.383,7.1175720872673764e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38112997,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,122,13,3,SGLT2i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,8.35,1.0,-0.826,9.62814272753576e-11,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT79105951,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,35,25,2,NovelSmallMolecule,Placebo,Triple,Non-Randomized,Crossover,Industry,Multi-Region,Composite,8.22,0.94,-0.007,0.9735863815387803,Completed,Has Results,Not met / not primary / not significant,0
NCT84903381,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,164,13,2,Insulin,Placebo,Single,Randomized,Parallel,Industry,Asia,HbA1c change,7.49,0.91,-1.254,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49169499,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,19,3,DPP-4i,Placebo,Open Label,Non-Randomized,Parallel,Industry,Other,HbA1c change,8.89,1.17,-0.834,1.5791080066884788e-06,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82428791,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,227,20,3,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.48,1.11,-1.014,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT85752267,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,46,26,2,DPP-4i,Active,Open Label,Randomized,Parallel,Government,North America,FPG change,8.86,1.15,-0.607,0.011412325696345316,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT44873053,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,150,14,2,Insulin,Placebo,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,7.6,1.15,-0.87,4.6662451680390404e-11,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90827885,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,12,2,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Asia,HbA1c change,8.65,1.08,-0.812,2.3028170625938316e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35949529,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,7,5,Other,Active,Open Label,Non-Randomized,Parallel,Industry,Asia,HbA1c change,8.54,0.84,-0.438,0.0006465395165844434,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT31560200,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,25,4,Other,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,Weight,8.5,0.92,-0.786,8.599041032786303e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT71424594,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,130,19,2,Insulin,Placebo,Triple,Non-Randomized,Parallel,Industry,Europe,CGM TIR,7.92,1.0,-0.994,1.2212453270876722e-15,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT67308563,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,19,3,Insulin,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.23,1.62,-0.796,5.230145629842031e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22577723,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,222,35,4,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,Asia,Composite,9.84,0.76,-0.767,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT84946306,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,157,18,3,SGLT2i,Active,Double,Non-Randomized,Parallel,Industry,Other,Composite,7.62,1.0,-0.613,4.952878840391861e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT82440919,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,8,3,NovelSmallMolecule,Active,Triple,Randomized,Parallel,Industry,North America,HbA1c change,8.9,1.12,-1.041,1.1525535081879923e-08,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT10662604,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,15,5,DPP-4i,Placebo,Single,Non-Randomized,Parallel,Academic,North America,HbA1c change,6.5,1.02,-0.469,0.01015183032612832,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81715831,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,10,5,GLP-1RA,DoseComparison,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.87,1.37,-0.793,0.002616863435452421,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80823193,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,193,14,2,GLP-1RA,Placebo,Double,Randomized,Single Group,Industry,Europe,HbA1c change,7.09,1.02,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80232787,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,14,2,NovelSmallMolecule,DoseComparison,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.03,1.04,-0.664,0.00016058204656621555,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69836576,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,194,12,2,GLP-1RA,Active,Open Label,Randomized,Single Group,Government,Europe,HbA1c change,7.48,1.3,-0.651,8.771453439138099e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT52441042,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,8,2,SGLT2i,Placebo,Double,Randomized,Crossover,Industry,Asia,Composite,8.25,1.55,-0.642,0.0010370619451383067,Completed,Has Results,Not met / not primary / not significant,0
NCT73464883,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,115,26,3,SGLT2i,Placebo,Open Label,Randomized,Single Group,Industry,Europe,HbA1c change,8.99,1.45,-0.175,0.36017857173220125,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT34940945,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,18,5,GLP-1RA,Active,Triple,Randomized,Crossover,Industry,Europe,CGM TIR,7.1,1.07,-0.522,0.001244891470395748,Completed,Has Results,Not met / not primary / not significant,0
NCT60008225,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,134,15,2,SGLT2i,Active,Single,Randomized,Parallel,Industry,North America,HbA1c change,8.15,1.09,-0.783,3.88416665497715e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51302419,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,99,21,5,NovelSmallMolecule,Placebo,Open Label,Randomized,Crossover,Industry,Multi-Region,HbA1c change,8.04,1.11,-0.8,4.0860980632384525e-07,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55504562,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,19,4,GLP-1RA,Active,Open Label,Randomized,Single Group,Academic,Europe,Weight,9.51,1.14,-1.486,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT61186707,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,136,18,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.7,0.89,-0.388,0.0003107717641274155,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT13353608,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,93,20,4,NovelSmallMolecule,Placebo,Single,Non-Randomized,Parallel,Industry,North America,HbA1c change,7.58,1.33,-0.435,0.026327845688034035,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22581729,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,69,17,4,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,8.07,1.15,-0.567,0.003833498263966173,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT32093304,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,130,20,5,GLP-1RA,Placebo,Single,Randomized,Single Group,Academic,Multi-Region,FPG change,9.49,1.09,-1.527,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT20307706,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,21,4,TZD,StandardOfCare,Open Label,Randomized,Parallel,Government,North America,HbA1c change,8.9,0.78,-0.821,2.680078381445128e-13,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49565221,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,124,17,2,GLP-1RA,Placebo,Double,Randomized,Crossover,Academic,North America,HbA1c change,7.76,1.12,-0.839,3.19698556516812e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70156265,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,15,2,DPP-4i,StandardOfCare,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.21,0.63,-0.824,1.1102230246251565e-16,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT68898596,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,25,3,Other,Placebo,Single,Randomized,Single Group,Academic,Asia,HbA1c change,8.24,0.95,-0.491,0.005580960134564439,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT52398658,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,217,13,2,Other,Active,Single,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.02,0.96,-0.269,0.0035083989494039125,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT86957199,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,200,18,6,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,7.2,1.17,-0.618,1.3038907564766333e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT17127766,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,148,18,6,SGLT2i,Placebo,Open Label,Randomized,Crossover,Industry,Europe,HbA1c change,7.93,1.57,-0.753,3.715259965797468e-05,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78849896,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,12,6,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Single Group,Academic,Multi-Region,HbA1c change,9.37,1.24,-0.56,0.003498360005158796,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT61714055,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,11,2,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Multi-Region,FPG change,8.13,1.46,-0.709,0.0013847569417350103,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT67124648,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,185,14,2,DPP-4i,Placebo,Triple,Randomized,Parallel,Academic,North America,FPG change,8.33,1.26,-0.891,1.1166956248587212e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT60883598,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,13,3,TZD,DoseComparison,Triple,Randomized,Parallel,Industry,North America,HbA1c change,8.5,1.38,,,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59822145,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,7,3,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.95,1.56,-0.876,0.0006087522123560118,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18150978,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,231,12,3,SGLT2i,StandardOfCare,Double,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.41,0.92,-0.756,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT60328643,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,18,2,Insulin,Placebo,Single,Randomized,Parallel,Academic,Asia,Composite,9.17,0.9,-1.244,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT81542134,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,220,24,6,GLP-1RA,Active,Double,Randomized,Parallel,Government,Asia,HbA1c change,7.98,1.27,-1.121,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT37355508,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,19,2,GLP-1RA,StandardOfCare,Double,Randomized,Crossover,Industry,Multi-Region,HbA1c change,8.22,1.1,-1.491,2.8972380050618085e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT64255441,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,4,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.41,1.16,-0.854,4.359910543705325e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT12773605,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,253,20,4,Other,Placebo,Double,Non-Randomized,Parallel,Industry,Europe,HbA1c change,7.86,1.04,-0.43,3.0927800900304447e-06,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT41274927,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,13,2,Insulin,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.26,0.95,-0.64,1.7201806988831336e-06,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49304564,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,19,3,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Other,Multi-Region,HbA1c change,9.02,1.51,-0.947,3.0139156084629803e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT98446454,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,59,16,2,Other,Active,Double,Randomized,Parallel,Industry,Asia,FPG change,7.84,0.83,0.132,0.3844562324819959,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT29312620,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,162,15,3,GLP-1RA,DoseComparison,Single,Randomized,Parallel,Industry,North America,HbA1c change,8.4,1.27,-0.857,1.2990463149620268e-09,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT34889349,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,15,3,DPP-4i,Active,Triple,Randomized,Parallel,Industry,North America,FPG change,8.9,1.23,-0.812,9.577599846088969e-05,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT46767577,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,16,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Other,Multi-Region,CGM TIR,7.82,0.71,-0.552,7.041337302116091e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT99339904,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,24,4,GLP-1RA,Placebo,Triple,Randomized,Single Group,Industry,Multi-Region,HbA1c change,9.17,0.89,-1.123,1.8137824575603645e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86806275,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,200,16,5,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Academic,Asia,Weight,8.45,0.93,-0.811,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT13122366,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,167,23,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,North America,FPG change,8.28,1.24,-0.459,0.0007341392251040135,Completed,Has Results,Not met / not primary / not significant,0
NCT31054553,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,22,2,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,CGM TIR,6.99,1.01,-0.349,0.015264914680969022,Completed,Has Results,Not met / not primary / not significant,0
NCT83950699,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,59,20,3,GLP-1RA,StandardOfCare,Open Label,Randomized,Parallel,Academic,Multi-Region,FPG change,8.14,1.08,-0.476,0.016512562648393292,Completed,Has Results,Not met / not primary / not significant,0
NCT15247246,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,199,5,4,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.66,0.74,-0.717,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT87010375,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,23,2,Other,Placebo,Double,Non-Randomized,Crossover,Academic,Asia,HbA1c change,9.62,1.68,-0.969,0.0001890498366846627,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35324549,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,13,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.8,1.12,-1.376,1.0404455075274655e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT92588690,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,45,20,2,SGLT2i,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,9.19,1.22,-0.9,0.0004909255624950815,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT36423437,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,74,10,4,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Asia,HbA1c change,7.55,0.96,-0.77,1.2049494467758493e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49088512,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,9,3,DPP-4i,Placebo,Single,Randomized,Parallel,Academic,Europe,HbA1c change,8.31,0.94,-0.65,0.00040564709563639667,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69572485,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,28,3,TZD,Active,Double,Randomized,Single Group,Industry,Europe,HbA1c change,9.25,1.58,-0.829,0.0013023161739752487,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21365266,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,139,10,4,DPP-4i,Placebo,Open Label,Non-Randomized,Parallel,Academic,Multi-Region,Weight,7.78,0.62,-0.42,1.6661064194956055e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT60132893,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,23,3,GLP-1RA,Active,Double,Randomized,Single Group,Other,Asia,FPG change,9.08,1.17,-0.955,1.2316997943795371e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT55451394,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,117,17,4,SGLT2i,Placebo,Single,Non-Randomized,Parallel,Industry,North America,HbA1c change,8.91,0.8,-1.044,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80550838,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,13,2,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.59,1.0,-0.041,0.8040088251678406,Completed,Has Results,Not met / not primary / not significant,0
NCT99649620,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,16,3,TZD,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.17,0.94,,,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69788217,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,236,8,4,TZD,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,Weight,7.71,0.85,,,Completed,Has Results,Not met / not primary / not significant,0
NCT46826779,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,16,3,NovelSmallMolecule,Placebo,Single,Randomized,Crossover,Academic,Other,FPG change,9.64,1.11,-0.813,1.7390606140699205e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT46574817,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,118,10,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,8.84,0.6,-0.915,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT47616286,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,49,14,3,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.64,1.02,-0.993,1.4705144418813987e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT83261833,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,197,22,2,DPP-4i,Placebo,Single,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.11,1.08,-0.68,3.679159199521109e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38909415,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,18,4,Insulin,Placebo,Double,Randomized,Parallel,Industry,Europe,FPG change,8.43,0.76,-1.135,0.0,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT25027562,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,160,7,3,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,North America,Composite,8.52,1.48,,,Completed,Has Results,Not met / not primary / not significant,0
NCT40086229,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,21,3,NovelSmallMolecule,DoseComparison,Single,Randomized,Single Group,Government,Other,HbA1c change,8.68,0.95,-0.496,0.0003502537807069661,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT12044086,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,16,5,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.91,1.04,-0.525,4.487606647929354e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19552832,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,13,2,NovelSmallMolecule,StandardOfCare,Open Label,Non-Randomized,Crossover,Industry,Asia,HbA1c change,7.85,0.95,,,Completed,Has Results,Not met / not primary / not significant,0
NCT18104307,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,20,3,NovelSmallMolecule,DoseComparison,Double,Randomized,Crossover,Government,Asia,HbA1c change,7.37,1.08,-0.291,0.08632519605338107,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT79439716,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,163,15,4,Insulin,Placebo,Double,Randomized,Parallel,Industry,Asia,Composite,8.46,1.43,-0.706,7.893169312267467e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT75012340,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,9,4,Other,Active,Double,Randomized,Parallel,Academic,North America,FPG change,7.18,1.72,-0.811,0.004945479028600874,Recruiting,Has Results,Not met / not primary / not significant,0
NCT72709370,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,141,27,4,TZD,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.17,1.29,-1.153,5.2513549064769904e-14,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51568950,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,16,2,NovelSmallMolecule,Active,Single,Randomized,Crossover,Industry,North America,HbA1c change,8.04,1.37,-0.907,2.063268352503478e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74535265,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,16,2,SGLT2i,Placebo,Triple,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.74,1.53,-0.637,0.0015115348027104902,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24514459,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,14,6,DPP-4i,Placebo,Double,Randomized,Parallel,Academic,North America,HbA1c change,9.79,1.16,-0.936,2.97261445236785e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT91055950,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,23,4,Insulin,Placebo,Triple,Randomized,Crossover,Academic,Asia,HbA1c change,7.04,1.49,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55094029,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,13,2,GLP-1RA,Placebo,Double,Randomized,Single Group,Government,Multi-Region,CGM TIR,9.99,1.3,-1.066,5.702268134455402e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT94424624,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,111,7,3,DPP-4i,DoseComparison,Open Label,Randomized,Parallel,Other,North America,FPG change,8.24,1.14,-0.422,0.005596233940810547,Completed,Has Results,Not met / not primary / not significant,0
NCT23708089,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,12,2,Other,DoseComparison,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.64,1.19,-1.362,3.3306690738754696e-16,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54759706,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,24,6,TZD,Placebo,Open Label,Randomized,Single Group,Academic,Multi-Region,FPG change,7.41,0.64,-0.467,6.122332309455025e-06,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT72668833,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,21,3,GLP-1RA,Active,Double,Randomized,Single Group,Industry,North America,FPG change,9.1,1.17,-1.075,1.7605494839756375e-10,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT54606327,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,14,2,SGLT2i,Placebo,Double,Randomized,Parallel,Other,North America,HbA1c change,8.43,0.71,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT50154064,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,24,2,SGLT2i,DoseComparison,Single,Randomized,Parallel,Academic,Europe,FPG change,8.36,0.69,-0.989,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT24959268,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,20,2,GLP-1RA,Placebo,Triple,Randomized,Parallel,Government,Multi-Region,HbA1c change,7.04,1.15,-1.137,1.1328271654065247e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT44291909,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,14,3,Other,DoseComparison,Open Label,Randomized,Parallel,Industry,Asia,CGM TIR,8.45,0.82,-0.836,1.1312890291215183e-08,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT31488963,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,286,15,4,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.99,1.1,-0.772,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT37136087,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,160,18,6,SGLT2i,Placebo,Double,Randomized,Parallel,Academic,Other,HbA1c change,8.23,1.13,-1.024,6.661338147750939e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71533058,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,112,11,6,TZD,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,9.22,1.15,-0.919,1.9572107268217565e-09,"Active, not recruiting",Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT66725432,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,169,16,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.19,0.87,-0.947,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT64647678,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,41,18,2,SGLT2i,Placebo,Double,Randomized,Parallel,Other,Europe,HbA1c change,7.95,1.32,-1.053,0.000317977730337593,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42563134,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,31,6,4,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Europe,CGM TIR,9.52,1.08,-0.712,0.009323470394466238,Completed,Has Results,Not met / not primary / not significant,0
NCT96372331,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,15,4,TZD,DoseComparison,Double,Randomized,Crossover,Industry,Europe,HbA1c change,8.43,1.21,-0.933,6.746590275330533e-07,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT17888492,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,14,2,Other,Active,Single,Non-Randomized,Parallel,Industry,Asia,HbA1c change,8.43,0.8,-0.508,0.0011054788561861706,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40833169,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,22,2,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,Composite,8.47,1.06,-0.735,3.4336941033830115e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT20620531,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,5,3,DPP-4i,Placebo,Open Label,Randomized,Parallel,Academic,Asia,HbA1c change,8.45,1.37,-0.704,0.00015520834369253667,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40504942,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,151,14,2,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Other,North America,HbA1c change,6.56,1.34,-0.264,0.0874754370454236,Completed,Has Results,Not met / not primary / not significant,0
NCT96570788,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,13,2,Other,DoseComparison,Double,Randomized,Parallel,Other,Europe,HbA1c change,8.27,0.9,-0.676,3.984228511100252e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42963717,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,119,22,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,7.45,0.96,-0.322,0.00997085437567824,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT91772261,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,16,6,Other,Placebo,Single,Randomized,Parallel,Academic,Asia,HbA1c change,9.54,0.85,-0.651,6.838972932410314e-08,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54555908,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,27,6,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,FPG change,9.51,0.94,-1.147,0.0,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT72973641,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,79,20,4,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Government,Europe,HbA1c change,9.0,0.75,-0.831,3.3836267121500896e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51167573,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,185,14,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.23,1.07,-1.222,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT33928296,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,17,4,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Single Group,Industry,North America,HbA1c change,7.69,1.26,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97225872,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,221,14,2,DPP-4i,Active,Open Label,Randomized,Crossover,Other,Multi-Region,Weight,7.94,0.9,-0.174,0.04321610029895562,Completed,Has Results,Not met / not primary / not significant,0
NCT33717237,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,21,2,Insulin,StandardOfCare,Triple,Randomized,Parallel,Government,North America,HbA1c change,9.76,1.08,-1.813,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80087580,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,139,8,3,TZD,DoseComparison,Double,Randomized,Parallel,Industry,Multi-Region,CGM TIR,7.92,1.04,-0.81,1.0195466693119215e-10,Completed,Has Results,Not met / not primary / not significant,0
NCT33502599,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,11,2,Other,StandardOfCare,Double,Randomized,Parallel,Academic,Europe,HbA1c change,6.75,1.36,-0.028,0.8881498176491645,Completed,Has Results,Not met / not primary / not significant,0
NCT74520116,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,19,2,Other,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.12,0.95,-0.471,0.0011010973384644185,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81010589,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,23,2,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.45,0.96,-1.094,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT50442534,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,4,4,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,9.56,0.89,-0.576,1.930361317470375e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76322763,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,30,24,3,NovelSmallMolecule,Placebo,Open Label,Non-Randomized,Parallel,Industry,North America,HbA1c change,9.13,0.82,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT34501740,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,30,15,2,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Other,FPG change,9.24,1.23,-0.314,0.32331721495967525,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT17132816,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,176,5,3,GLP-1RA,StandardOfCare,Triple,Randomized,Parallel,Industry,North America,HbA1c change,8.44,1.07,-0.966,0.0,"Active, not recruiting",Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18675186,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,173,4,4,GLP-1RA,DoseComparison,Single,Randomized,Crossover,Industry,Europe,HbA1c change,6.95,1.11,-0.814,1.0394352045750566e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT50232134,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,233,7,5,NovelSmallMolecule,Active,Double,Randomized,Crossover,Industry,Europe,HbA1c change,8.42,1.42,-0.061,0.6413640505201248,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT91234214,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,99,16,5,DPP-4i,Placebo,Double,Randomized,Parallel,Other,Asia,HbA1c change,8.84,1.43,-0.709,0.0005004769438592405,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21481916,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,56,16,3,Other,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.31,0.69,-0.639,9.002116588829878e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51019865,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,20,3,DPP-4i,Placebo,Open Label,Randomized,Parallel,Government,North America,HbA1c change,8.27,1.26,-0.275,0.1625319116319205,Completed,Has Results,Not met / not primary / not significant,0
NCT73362884,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,13,6,Other,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.73,1.16,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT28212702,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,9,5,DPP-4i,Placebo,Single,Randomized,Parallel,Academic,Asia,HbA1c change,7.7,0.98,-0.293,0.09490205480420999,Completed,Has Results,Not met / not primary / not significant,0
NCT74945475,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,209,14,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Government,Other,HbA1c change,9.69,1.18,-0.355,0.0021174729284875182,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT37536095,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,273,16,4,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.71,0.67,-1.246,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82779466,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,17,4,Insulin,StandardOfCare,Open Label,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.4,1.47,-0.459,0.01402191615022963,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62129760,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,99,11,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.6,1.23,-0.424,0.015269589701244812,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59221653,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,56,21,4,Other,DoseComparison,Single,Randomized,Parallel,Industry,Europe,Weight,7.71,0.88,-0.36,0.0311176064620734,Completed,Has Results,Not met / not primary / not significant,0
NCT25909550,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,200,12,3,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.85,0.95,-0.746,4.9960036108132044e-15,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51688531,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,11,2,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Asia,CGM TIR,9.63,0.67,-0.829,0.0,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT87095284,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,13,3,DPP-4i,Placebo,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,7.33,1.02,-0.355,0.022040265392717417,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11757159,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,124,22,5,GLP-1RA,Placebo,Double,Non-Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.72,0.98,-1.204,0.0,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78266756,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,15,2,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.78,0.77,-1.13,0.0,"Active, not recruiting",Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54348614,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,12,4,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.77,1.29,-1.221,6.462164137133186e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74751665,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,22,4,NovelSmallMolecule,Placebo,Single,Randomized,Parallel,Academic,North America,FPG change,9.55,1.42,-1.452,1.8075518670723767e-07,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT69696820,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,162,29,2,NovelSmallMolecule,DoseComparison,Double,Randomized,Crossover,Industry,Other,CGM TIR,9.83,1.09,-0.908,7.66053886991358e-14,Completed,Has Results,Not met / not primary / not significant,0
NCT48888373,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,17,3,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.24,1.02,-1.041,2.4302782009044677e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT37780047,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,168,23,4,NovelSmallMolecule,Placebo,Single,Randomized,Parallel,Industry,North America,FPG change,8.87,1.21,-0.338,0.010438871462147725,Completed,Has Results,Not met / not primary / not significant,0
NCT66457795,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,22,3,NovelSmallMolecule,Placebo,Open Label,Non-Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.46,1.1,-0.468,0.003934090293385872,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22620184,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,12,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.96,0.83,-1.474,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62568816,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,16,6,SGLT2i,Placebo,Single,Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.59,0.94,-0.615,0.0004096712260559521,Completed,Has Results,Not met / not primary / not significant,0
NCT18522522,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,8,3,TZD,Placebo,Double,Randomized,Single Group,Industry,Other,HbA1c change,8.87,1.03,-0.777,2.343051308528743e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT68486193,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,67,15,3,NovelSmallMolecule,Active,Open Label,Non-Randomized,Parallel,Other,North America,HbA1c change,8.55,1.16,-0.515,0.010263254150278733,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT66587075,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,12,2,GLP-1RA,DoseComparison,Single,Randomized,Parallel,Other,Multi-Region,Weight,7.78,1.1,-1.145,5.0813131480254015e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT17599988,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,14,2,Insulin,Placebo,Double,Randomized,Parallel,Industry,Europe,Composite,8.08,1.15,-1.19,2.916555885690286e-13,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT78173909,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,12,2,NovelSmallMolecule,Active,Double,Non-Randomized,Parallel,Industry,Asia,HbA1c change,8.08,0.72,-0.652,4.8147041908919164e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT47422665,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,46,14,4,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Europe,HbA1c change,7.81,1.27,-1.205,5.004007786357789e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80819780,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,19,4,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Government,North America,CGM TIR,8.62,1.1,-0.483,0.0032412789524511876,Completed,Has Results,Not met / not primary / not significant,0
NCT13745275,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,142,15,4,Other,Active,Double,Randomized,Parallel,Academic,Asia,HbA1c change,8.69,1.74,-0.3,0.14619398800495664,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT26151084,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,5,2,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.09,1.0,-0.92,2.7976576610910797e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54459173,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,12,2,SGLT2i,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.8,1.18,-1.218,4.490186000793983e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT26940265,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,107,7,5,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,Weight,8.0,1.81,-0.806,0.0011125538731449058,Completed,Has Results,Not met / not primary / not significant,0
NCT39687508,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,17,3,SGLT2i,Placebo,Double,Randomized,Parallel,Government,Asia,Weight,9.49,1.15,-0.738,1.052778470045368e-05,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT69453913,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,19,2,NovelSmallMolecule,Placebo,Triple,Randomized,Crossover,Government,North America,FPG change,8.28,1.08,-0.779,5.387676564971855e-05,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT23007176,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,18,6,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.42,0.85,-0.663,5.2519860127553386e-08,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70993264,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,156,11,4,TZD,DoseComparison,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.28,1.48,-0.858,3.211083535736847e-07,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19306266,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,17,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.19,0.81,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25766665,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,13,5,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Academic,Asia,Weight,9.22,1.21,-0.999,8.143586693876159e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT62888010,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,9,2,Other,Placebo,Triple,Randomized,Parallel,Other,North America,HbA1c change,9.18,0.98,-0.523,0.006129258540994886,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81413490,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,152,20,2,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.42,1.05,-1.13,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25353366,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,21,3,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,FPG change,7.79,0.74,-0.389,0.0003093987261346687,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT36999350,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,22,4,SGLT2i,Active,Double,Randomized,Single Group,Industry,North America,HbA1c change,9.75,1.44,-0.977,7.194574294888678e-05,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93260809,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,104,12,4,NovelSmallMolecule,Active,Open Label,Randomized,Parallel,Industry,Multi-Region,CGM TIR,9.0,1.03,,,Completed,Has Results,Not met / not primary / not significant,0
NCT99071531,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,23,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.08,0.8,-0.487,0.000995785781354508,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62295501,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,13,3,Other,Placebo,Double,Randomized,Parallel,Industry,North America,CGM TIR,9.4,1.41,,,Completed,Has Results,Not met / not primary / not significant,0
NCT50233433,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,20,3,SGLT2i,Active,Double,Randomized,Parallel,Government,Asia,HbA1c change,8.03,0.97,-0.53,0.005569537535513369,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT41218282,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,13,5,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.39,1.18,-0.243,0.253063318778737,Completed,Has Results,Not met / not primary / not significant,0
NCT65120672,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,183,15,5,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,9.43,1.31,-1.216,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63182393,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,4,2,Insulin,Placebo,Double,Non-Randomized,Parallel,Industry,North America,HbA1c change,7.75,1.22,-1.308,1.1829948132202617e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT36527772,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,14,6,Other,Placebo,Double,Randomized,Parallel,Industry,Other,HbA1c change,8.81,0.6,-0.235,0.00216605017001259,Completed,Has Results,Not met / not primary / not significant,0
NCT12052348,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,17,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.95,1.27,-1.064,1.113436280286706e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT23634847,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,14,4,TZD,Placebo,Double,Randomized,Single Group,Academic,Asia,HbA1c change,10.23,1.07,-0.551,1.7841163075460464e-05,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT96270328,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,27,4,DPP-4i,Placebo,Open Label,Non-Randomized,Parallel,Industry,North America,FPG change,7.88,1.02,-0.199,0.2736283525004761,Completed,Has Results,Not met / not primary / not significant,0
NCT47633941,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,9,2,Other,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.4,1.07,-0.991,5.206324260598194e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53407308,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,13,2,DPP-4i,DoseComparison,Open Label,Randomized,Single Group,Industry,Europe,FPG change,8.41,0.7,,,Completed,Has Results,Not met / not primary / not significant,0
NCT52039679,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,284,11,3,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Asia,CGM TIR,7.53,1.15,,,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT80446169,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,13,3,DPP-4i,Placebo,Double,Randomized,Parallel,Government,Other,HbA1c change,8.32,0.76,-0.972,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT15846090,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,22,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Other,North America,CGM TIR,8.4,1.03,-1.013,1.2833973883630279e-09,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT17445699,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,25,5,SGLT2i,Placebo,Open Label,Randomized,Single Group,Industry,North America,HbA1c change,7.66,1.14,-0.506,0.0002640582881100473,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT34826251,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,260,12,3,GLP-1RA,Active,Single,Randomized,Parallel,Academic,Europe,HbA1c change,8.62,1.37,-1.145,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53799249,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,48,12,2,DPP-4i,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,9.07,0.9,-0.588,0.0013015293141729334,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70401162,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,9,5,TZD,Active,Open Label,Randomized,Single Group,Other,Multi-Region,CGM TIR,8.57,1.46,-0.388,0.12193462983674785,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT54163628,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,24,3,SGLT2i,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.02,1.34,,,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT49705126,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,23,4,DPP-4i,DoseComparison,Double,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.3,0.99,-0.592,0.00013335760478150327,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24491704,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,15,2,Other,Placebo,Double,Randomized,Crossover,Industry,North America,Composite,8.4,0.82,-0.377,0.002635881882834923,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT61455524,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,8,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Single Group,Government,Europe,HbA1c change,8.55,0.74,-0.538,0.00013620449429629922,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT58802019,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,187,8,3,Insulin,Placebo,Single,Non-Randomized,Parallel,Academic,Multi-Region,Weight,9.18,1.17,-1.17,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT52614045,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,17,5,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Europe,FPG change,8.59,0.92,-0.766,2.0166190531689665e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT82683768,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,19,3,Other,StandardOfCare,Double,Non-Randomized,Parallel,Industry,Asia,Weight,7.42,1.4,0.161,0.43724232502650406,Completed,Has Results,Not met / not primary / not significant,0
NCT34027809,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,159,4,2,SGLT2i,Active,Double,Randomized,Parallel,Academic,North America,Weight,8.01,0.93,-0.894,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT95839556,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,14,2,SGLT2i,StandardOfCare,Single,Non-Randomized,Parallel,Government,Europe,Composite,8.52,0.87,-0.534,1.9267146771473342e-05,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT39841209,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,26,3,Other,Placebo,Single,Randomized,Single Group,Industry,Multi-Region,HbA1c change,9.19,1.16,-0.592,0.0038315861187248057,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59050402,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,15,5,Insulin,Active,Open Label,Randomized,Parallel,Academic,North America,CGM TIR,9.31,0.93,-1.24,3.957723038183758e-12,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT56860515,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,25,4,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,Other,CGM TIR,9.64,1.1,-0.887,6.810783359512129e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT86480009,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,20,5,TZD,Active,Open Label,Randomized,Parallel,Industry,Europe,FPG change,8.49,1.35,-0.66,0.0034785518483128053,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT49502030,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,9,2,TZD,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.93,1.13,-0.891,5.621597187754901e-09,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35610306,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,14,3,SGLT2i,Active,Double,Randomized,Parallel,Academic,North America,Composite,7.38,1.13,-0.734,0.0008313335220218043,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT11945087,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,143,15,3,SGLT2i,Active,Triple,Non-Randomized,Parallel,Other,North America,HbA1c change,8.7,1.15,-0.802,3.864845110612691e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42731042,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,10,6,SGLT2i,DoseComparison,Double,Randomized,Crossover,Industry,Asia,HbA1c change,7.65,0.68,-0.271,0.0037092130750429053,Completed,Has Results,Not met / not primary / not significant,0
NCT84366272,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,10,4,GLP-1RA,Placebo,Double,Non-Randomized,Parallel,Industry,North America,HbA1c change,8.36,1.2,-0.692,2.2015184704127222e-05,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT10892457,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,190,25,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,10.52,1.14,,,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90654468,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,10,2,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,FPG change,8.61,1.32,-0.448,0.030322340839745276,Completed,Has Results,Not met / not primary / not significant,0
NCT58854437,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,22,4,Insulin,Placebo,Single,Randomized,Parallel,Industry,Europe,HbA1c change,7.8,1.25,-1.232,3.4448114361040894e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22622417,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,13,4,NovelSmallMolecule,Active,Double,Randomized,Crossover,Industry,North America,FPG change,8.69,1.05,-0.04,0.8111018603332346,Completed,Has Results,Not met / not primary / not significant,0
NCT37196139,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,16,2,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Europe,Weight,8.04,1.36,,,Completed,Has Results,Not met / not primary / not significant,0
NCT59863252,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,19,4,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.73,1.03,-0.773,2.148770189558391e-07,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38412294,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,12,6,DPP-4i,Active,Double,Non-Randomized,Crossover,Industry,Asia,FPG change,9.87,1.16,-0.541,0.006577609902528869,Completed,Has Results,Not met / not primary / not significant,0
NCT19771816,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,40,19,5,Other,Placebo,Triple,Randomized,Parallel,Academic,North America,HbA1c change,9.15,1.02,-1.031,6.512691553828276e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69938998,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,4,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Asia,Weight,8.64,1.22,-0.675,0.0005733951589244057,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT70501607,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,117,19,4,NovelSmallMolecule,Active,Double,Randomized,Single Group,Industry,Europe,Composite,8.13,1.01,-0.159,0.2255284256689709,Completed,Has Results,Not met / not primary / not significant,0
NCT20698682,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,4,5,Other,Active,Open Label,Randomized,Parallel,Other,Europe,HbA1c change,8.18,1.51,-0.321,0.12187213112618156,Completed,Has Results,Not met / not primary / not significant,0
NCT35311040,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,171,15,4,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,North America,FPG change,9.48,1.6,-0.629,0.00029030555693410065,Completed,Has Results,Not met / not primary / not significant,0
NCT31948592,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,240,21,2,SGLT2i,Placebo,Single,Randomized,Parallel,Industry,Other,HbA1c change,8.61,1.32,-0.783,7.708822469254528e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69348036,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,20,3,Insulin,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,6.5,1.49,-1.194,1.741384814124558e-11,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75726602,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,185,8,2,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,North America,FPG change,10.09,0.72,-1.006,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT75429514,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,9,5,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.53,0.74,-1.233,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT94488510,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,215,12,5,Other,Placebo,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,8.64,1.02,-0.871,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT79178273,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,229,17,3,Insulin,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,9.16,1.11,-1.305,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38861149,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,153,4,5,DPP-4i,Placebo,Open Label,Randomized,Single Group,Industry,North America,HbA1c change,8.73,1.05,-0.343,0.00429272796182989,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19696685,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,137,16,3,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,Weight,8.92,0.69,-1.091,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT65317853,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,18,2,Other,StandardOfCare,Open Label,Randomized,Single Group,Industry,Asia,HbA1c change,8.1,1.39,-0.304,0.13909004284158633,Completed,Has Results,Not met / not primary / not significant,0
NCT92441065,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,14,5,GLP-1RA,Active,Single,Randomized,Parallel,Industry,North America,HbA1c change,7.54,1.64,-1.141,1.0878233371869328e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97763977,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,19,2,GLP-1RA,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.6,1.42,-0.582,0.007600494034256666,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30719258,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,17,2,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Europe,Weight,9.4,1.37,-0.899,1.0222679236449039e-07,Recruiting,Has Results,Not met / not primary / not significant,0
NCT31280989,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,13,3,GLP-1RA,Placebo,Open Label,Randomized,Crossover,Industry,North America,HbA1c change,7.95,1.16,-0.908,2.469390967929641e-06,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22713593,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,4,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Other,HbA1c change,7.89,0.89,-0.453,0.00058229520455233,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59936721,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,34,17,3,Insulin,Placebo,Double,Non-Randomized,Single Group,Industry,Multi-Region,HbA1c change,9.25,1.12,-0.903,0.0008714467773518475,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59212295,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,216,10,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.08,1.63,-0.943,1.672411209518998e-09,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT43383005,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,13,2,GLP-1RA,Placebo,Double,Non-Randomized,Parallel,Other,Multi-Region,Composite,8.11,1.01,-0.775,2.79251704760064e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT37895989,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,122,19,2,GLP-1RA,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.14,0.99,-0.993,3.774758283725532e-15,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84681076,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,192,25,2,DPP-4i,Active,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.35,1.38,-0.609,1.4513550217198912e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51403053,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,114,16,5,GLP-1RA,Placebo,Double,Randomized,Parallel,Other,Multi-Region,CGM TIR,7.3,1.39,-1.106,2.083458072732469e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT82742631,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,191,19,6,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.02,0.89,-0.825,0.0,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT96689067,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,7,6,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.56,1.03,-1.178,1.2041772023962949e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38542500,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,293,17,3,SGLT2i,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.56,0.97,,,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT95760944,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,162,16,2,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.21,1.12,-0.857,5.148992343606551e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67134797,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,23,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Academic,North America,FPG change,9.69,1.38,-0.859,4.034905555672097e-06,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT36182605,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,189,13,4,GLP-1RA,StandardOfCare,Open Label,Randomized,Parallel,Industry,Other,Weight,9.46,0.9,-1.04,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT65967398,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,59,15,3,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Asia,Weight,9.04,1.37,,,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT56355141,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,22,3,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Academic,Asia,Weight,8.3,1.13,-0.222,0.1934359986802665,Recruiting,Has Results,Not met / not primary / not significant,0
NCT91497896,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,191,15,2,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Asia,HbA1c change,7.96,1.68,-1.004,5.339935382764338e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT33036857,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,43,9,3,Insulin,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.41,1.18,-1.116,1.1573937197417727e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT99224451,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,31,5,DPP-4i,Placebo,Open Label,Randomized,Single Group,Industry,North America,FPG change,8.81,1.08,-0.76,1.587781151002332e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT94243920,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,10,2,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Other,Composite,8.98,1.24,-0.255,0.10420518599320217,Completed,Has Results,Not met / not primary / not significant,0
NCT26263179,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,241,16,3,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,FPG change,8.84,1.02,,,Completed,Has Results,Not met / not primary / not significant,0
NCT24814703,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,49,18,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Single Group,Government,Asia,HbA1c change,8.32,0.65,-0.629,1.7329874646421217e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57984114,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,205,18,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Europe,FPG change,8.95,1.04,-0.291,0.00465118872397241,Completed,Has Results,Not met / not primary / not significant,0
NCT14041955,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,15,4,SGLT2i,Placebo,Open Label,Randomized,Parallel,Industry,North America,CGM TIR,9.28,1.04,-0.757,5.8124097147560505e-06,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT36891816,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,15,6,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,North America,Weight,9.02,0.7,-1.118,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT49158734,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,15,2,SGLT2i,Placebo,Open Label,Randomized,Single Group,Industry,Europe,CGM TIR,8.38,1.08,-0.888,1.1686482834671885e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT97243596,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,9,6,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.82,0.6,-0.687,2.512174912538967e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT99313799,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,119,29,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Other,Asia,HbA1c change,7.8,1.01,-0.263,0.045016139078255524,Completed,Has Results,Not met / not primary / not significant,0
NCT23638594,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,15,2,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.92,1.16,-1.085,3.0327474342950467e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90250953,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,139,20,2,SGLT2i,DoseComparison,Double,Randomized,Single Group,Industry,Europe,HbA1c change,8.58,1.12,-1.305,0.0,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18183594,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,74,14,2,Other,Placebo,Double,Randomized,Single Group,Other,Europe,Composite,8.76,1.0,,,Completed,Has Results,Not met / not primary / not significant,0
NCT86107842,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,14,4,GLP-1RA,Active,Triple,Non-Randomized,Parallel,Industry,Asia,HbA1c change,7.41,1.08,-0.954,1.910007692451643e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90171323,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,13,2,DPP-4i,StandardOfCare,Open Label,Randomized,Parallel,Other,North America,HbA1c change,8.05,0.9,-0.224,0.12228944259878582,Completed,Has Results,Not met / not primary / not significant,0
NCT30107614,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,7,2,NovelSmallMolecule,DoseComparison,Double,Non-Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.57,1.1,-0.422,0.0035885452653856564,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90410196,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,15,4,GLP-1RA,Active,Open Label,Non-Randomized,Parallel,Industry,Europe,FPG change,7.77,1.11,-0.99,3.851441054969484e-09,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT20438281,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,14,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Other,North America,HbA1c change,8.7,0.87,-1.138,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56697251,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,136,23,2,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.18,1.17,-0.758,8.483377245127599e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT52259076,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,162,9,4,Other,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,Weight,7.89,1.17,-0.118,0.36092529253883776,Completed,Has Results,Not met / not primary / not significant,0
NCT38433614,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,13,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.44,1.06,-1.127,2.151723244026016e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11990275,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,11,2,SGLT2i,Placebo,Single,Randomized,Parallel,Academic,Asia,HbA1c change,8.67,1.71,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT79481118,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,25,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.81,1.06,-0.69,3.3197743696256055e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40202528,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,11,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.23,1.03,-0.821,4.021492028272178e-10,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69549513,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,19,5,TZD,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,FPG change,8.73,0.99,-0.759,9.997147507156967e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT46919792,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,67,22,3,SGLT2i,Placebo,Double,Non-Randomized,Single Group,Academic,North America,Weight,7.87,0.86,-0.762,2.722197873783472e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT43629195,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,15,2,Insulin,Active,Single,Randomized,Parallel,Industry,North America,HbA1c change,7.24,1.27,-1.003,2.2140201183518116e-06,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT89766631,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,8,5,TZD,Active,Single,Randomized,Parallel,Industry,Asia,Composite,7.32,0.93,-0.743,6.767451654621226e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT76295561,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,8,4,NovelSmallMolecule,StandardOfCare,Single,Non-Randomized,Parallel,Industry,Multi-Region,FPG change,8.11,0.96,,,Completed,Has Results,Not met / not primary / not significant,0
NCT77211064,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,137,21,3,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,7.48,0.97,-0.993,0.0,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT44199230,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,48,8,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.16,0.85,-0.467,0.007341317778925993,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT33621446,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,49,18,6,TZD,StandardOfCare,Double,Randomized,Parallel,Industry,Other,HbA1c change,9.57,0.66,-1.138,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT10477636,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,17,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,Weight,7.43,0.98,-0.461,0.002150299882935025,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT94313182,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,18,2,NovelSmallMolecule,DoseComparison,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.2,1.32,-0.873,7.154486475036137e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT95295830,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,19,2,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,9.89,1.15,-0.659,0.0034383565122282356,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT31687351,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,10,3,SGLT2i,StandardOfCare,Double,Non-Randomized,Parallel,Industry,Asia,FPG change,8.69,1.49,-0.451,0.06184374026622186,Completed,Has Results,Not met / not primary / not significant,0
NCT12871994,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,10,6,Other,Placebo,Open Label,Randomized,Parallel,Other,Europe,Weight,8.14,1.29,-0.63,0.0016103677402464767,Completed,Has Results,Not met / not primary / not significant,0
NCT21048213,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,20,6,DPP-4i,Placebo,Open Label,Randomized,Parallel,Other,Europe,FPG change,8.29,1.23,,,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT16087857,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,107,12,3,TZD,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.7,1.57,-0.838,9.46665224570431e-05,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT84800139,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,74,4,4,Other,Active,Open Label,Randomized,Parallel,Other,Multi-Region,HbA1c change,9.59,1.08,-0.516,0.0035391658642182078,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90272029,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,193,20,2,DPP-4i,DoseComparison,Double,Randomized,Parallel,Government,Other,Weight,8.03,1.12,-0.619,4.9565497151071725e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT23795588,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,124,10,2,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,7.87,1.1,-0.822,3.6227298938484864e-09,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT77206550,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,69,19,4,SGLT2i,Active,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,7.43,1.49,-0.481,0.05723323859346929,Completed,Has Results,Not met / not primary / not significant,0
NCT26134147,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,104,24,2,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Asia,Composite,8.47,1.1,-0.738,1.3191887320296303e-06,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT43048809,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,16,4,TZD,Placebo,Open Label,Randomized,Single Group,Academic,Asia,HbA1c change,7.42,0.94,-0.811,3.639308854275214e-10,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63944450,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,172,22,4,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,Europe,HbA1c change,8.08,1.25,-1.161,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74793410,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,17,4,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,FPG change,7.76,0.9,-0.731,4.936526952770137e-07,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT88710582,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,141,26,3,SGLT2i,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,9.15,1.23,-0.47,0.001368475615256659,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT14030635,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,10,6,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Other,North America,HbA1c change,8.04,1.2,-0.801,2.257833694452316e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT27679119,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,195,16,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.68,1.05,-1.26,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35245775,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,178,20,4,SGLT2i,Active,Triple,Randomized,Parallel,Industry,Asia,CGM TIR,7.28,1.24,-0.487,0.00021666462498803885,Completed,Has Results,Not met / not primary / not significant,0
NCT37929130,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,15,2,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.49,0.73,-1.179,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT99822506,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,23,3,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,7.56,1.14,-0.643,0.00018470340944520824,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT79966434,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,125,13,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Government,Asia,HbA1c change,8.1,0.98,-0.676,5.719115214741777e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38837550,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,28,3,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Academic,Europe,CGM TIR,9.95,1.82,-1.098,4.086251611401526e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT97464377,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,212,29,2,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,9.05,1.14,-0.831,5.950795411990839e-14,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54937628,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,18,3,SGLT2i,Placebo,Double,Non-Randomized,Parallel,Industry,North America,HbA1c change,8.31,0.95,-0.698,1.3944853216596442e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55066706,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,19,3,Other,Active,Double,Non-Randomized,Single Group,Industry,Multi-Region,HbA1c change,10.64,0.76,-0.679,7.068304386237401e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49032895,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,23,2,TZD,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.76,1.43,-0.802,0.0003444659942328787,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22950775,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,9,2,GLP-1RA,Placebo,Double,Non-Randomized,Parallel,Academic,Asia,HbA1c change,9.22,1.01,-0.997,1.1365921770423171e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT94093522,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,8,3,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Academic,Asia,FPG change,7.33,0.9,-0.897,1.7763568394002505e-15,Completed,Has Results,Not met / not primary / not significant,0
NCT11254265,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,69,24,2,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,North America,Composite,8.23,1.18,-0.397,0.04918378274996893,"Active, not recruiting",Has Results,Not met / not primary / not significant,0
NCT25685067,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,163,18,6,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Asia,HbA1c change,7.46,1.26,-0.856,9.276349688391861e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30669042,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,56,15,2,Insulin,Placebo,Single,Randomized,Parallel,Industry,Europe,FPG change,8.58,1.26,-0.785,0.0009714320013021194,Completed,Has Results,Not met / not primary / not significant,0
NCT35136775,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,16,3,Other,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.44,1.1,-0.501,0.0010116630036661745,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21863999,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,167,4,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.18,1.14,-1.124,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11616527,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,38,15,5,GLP-1RA,StandardOfCare,Triple,Randomized,Parallel,Academic,Multi-Region,CGM TIR,9.16,1.16,-0.839,0.0015944133511349712,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT70989279,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,247,11,3,Other,StandardOfCare,Double,Randomized,Single Group,Industry,North America,HbA1c change,8.0,1.18,-0.608,1.1457662485447884e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97237891,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,22,4,TZD,Placebo,Double,Randomized,Parallel,Other,Asia,Composite,8.63,1.21,-0.854,5.781391153591997e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT20964925,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,22,3,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.97,1.37,-1.147,1.2073854138705542e-09,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT36688168,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,19,2,Other,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,7.36,1.11,-0.529,0.000136730564865295,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55569693,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,138,18,3,Other,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,7.88,0.9,-0.304,0.004789105250123327,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93475211,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,113,7,4,Insulin,Active,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.44,1.06,-1.302,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT72483618,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,156,20,6,TZD,DoseComparison,Open Label,Randomized,Parallel,Industry,Asia,Weight,8.84,1.29,-0.722,7.500835015328278e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT78956930,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,20,4,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,North America,FPG change,9.39,0.65,-0.804,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT62300494,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,220,23,4,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Academic,Europe,HbA1c change,8.25,0.65,-0.828,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT47533220,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,29,2,TZD,Placebo,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.18,1.33,-0.512,0.0022485261815926583,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT27979808,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,241,6,3,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Academic,Asia,FPG change,7.79,1.48,-0.48,0.00037301878717632686,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT87788293,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,149,14,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Single Group,Academic,Asia,CGM TIR,8.63,0.78,-0.241,0.007833725969713101,Completed,Has Results,Not met / not primary / not significant,0
NCT82371206,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,44,12,3,NovelSmallMolecule,Placebo,Triple,Randomized,Crossover,Industry,North America,HbA1c change,8.19,1.13,-0.646,0.007104110901236638,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT12259119,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,322,17,2,GLP-1RA,Active,Double,Randomized,Single Group,Industry,Asia,HbA1c change,8.21,1.0,-1.413,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74386640,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,16,4,TZD,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.33,1.03,-1.264,3.47499806707674e-14,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT17594929,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,195,15,2,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.79,1.18,-0.661,2.9000629897524277e-08,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76508559,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,22,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.01,0.78,-0.584,9.117003219039077e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84335845,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,160,9,3,SGLT2i,Placebo,Double,Randomized,Single Group,Other,Europe,HbA1c change,7.86,0.82,-0.789,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21795197,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,73,10,3,TZD,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.7,1.02,-1.12,4.0906722453826205e-11,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49045227,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,10,3,Insulin,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,6.5,1.06,-1.09,1.1102230246251565e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21137842,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,14,2,DPP-4i,Active,Double,Randomized,Parallel,Academic,Europe,HbA1c change,7.98,0.82,-0.68,3.032516215917269e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT61055398,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,202,9,3,NovelSmallMolecule,Active,Single,Randomized,Parallel,Academic,North America,Weight,7.59,1.3,-0.506,8.883946078974692e-05,Recruiting,Has Results,Not met / not primary / not significant,0
NCT93480628,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,121,16,2,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.24,1.0,-0.568,9.2617117817273e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT17278259,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,152,15,2,Insulin,Placebo,Triple,Randomized,Parallel,Academic,Asia,HbA1c change,8.09,0.99,-1.139,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT45782037,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,38,11,3,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Industry,North America,HbA1c change,8.01,1.17,-0.425,0.11313871641244644,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT97580845,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,21,2,Other,DoseComparison,Double,Randomized,Crossover,Industry,Multi-Region,HbA1c change,8.37,1.07,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT37085381,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,16,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,Weight,7.98,1.31,-0.767,5.771332041826227e-06,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT21899503,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,110,22,4,Insulin,Active,Double,Randomized,Crossover,Industry,Asia,HbA1c change,8.12,0.87,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53972563,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,153,15,3,GLP-1RA,StandardOfCare,Triple,Randomized,Parallel,Government,Europe,HbA1c change,8.47,0.75,-0.387,6.622463346594998e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55753531,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,16,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Crossover,Industry,Multi-Region,Weight,8.1,1.02,-0.345,0.028934355893146413,Completed,Has Results,Not met / not primary / not significant,0
NCT69657778,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,13,3,Insulin,Placebo,Open Label,Non-Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.1,1.12,-0.469,0.0026694772227806585,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT38236379,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,169,16,3,DPP-4i,Placebo,Double,Randomized,Single Group,Industry,Europe,CGM TIR,7.69,0.79,-0.623,3.9690473130349346e-13,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT96006092,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,36,20,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.59,0.75,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56892046,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,130,14,6,Other,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.44,1.15,-0.729,2.9005314172714236e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35780160,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,19,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,FPG change,8.61,0.91,-0.811,5.253036450270088e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT96425599,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,11,4,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Academic,North America,HbA1c change,7.4,0.74,-0.592,3.881942728600762e-06,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93232757,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,21,4,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,Europe,FPG change,8.93,1.34,-0.678,0.00011838355001470013,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT54924829,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,173,13,2,Other,StandardOfCare,Double,Randomized,Parallel,Academic,North America,CGM TIR,8.93,0.94,-0.256,0.011598735750813494,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT12237354,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,159,21,2,GLP-1RA,Placebo,Double,Non-Randomized,Single Group,Industry,Multi-Region,HbA1c change,9.08,1.39,-1.144,1.9950707752514063e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63724249,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,16,4,SGLT2i,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,8.61,1.11,-0.915,1.4657119740135727e-08,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59967823,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,148,25,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,Asia,HbA1c change,8.85,1.17,-0.985,5.119238366546597e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT23338758,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,147,9,4,Other,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.93,1.05,-1.003,2.220446049250313e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67057759,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,7,2,SGLT2i,DoseComparison,Double,Randomized,Crossover,Industry,North America,FPG change,8.19,0.6,-0.692,1.4432899320127035e-15,Completed,Has Results,Not met / not primary / not significant,0
NCT85671420,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,73,12,3,DPP-4i,Placebo,Double,Randomized,Crossover,Other,North America,CGM TIR,7.67,0.82,-0.562,3.11163204635978e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT19530766,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,8,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.33,1.07,-0.377,0.03084396528128497,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75099036,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,145,8,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Single Group,Academic,Multi-Region,FPG change,9.63,1.19,-0.807,8.001237561394703e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT22630563,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,20,4,DPP-4i,Placebo,Single,Randomized,Parallel,Industry,North America,HbA1c change,9.64,0.65,-0.968,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT77394363,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,16,2,Insulin,Placebo,Double,Randomized,Crossover,Industry,Multi-Region,FPG change,7.75,1.09,,,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT47720288,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,47,13,2,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Europe,HbA1c change,7.89,0.82,-0.662,9.077511181987408e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT10585992,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,145,14,2,NovelSmallMolecule,Active,Double,Randomized,Parallel,Government,North America,FPG change,8.17,1.16,-0.926,1.0127232386025753e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT96960871,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,12,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Industry,Asia,FPG change,9.26,1.1,-0.586,0.000827843876903489,Completed,Has Results,Not met / not primary / not significant,0
NCT24937333,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,115,26,4,Insulin,Placebo,Double,Randomized,Parallel,Academic,North America,HbA1c change,7.5,1.29,-0.972,1.001390814714398e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63643829,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,174,12,4,GLP-1RA,DoseComparison,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,7.02,1.37,-0.938,1.5575152279012627e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT26332140,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,8,4,Other,StandardOfCare,Double,Randomized,Crossover,Industry,Asia,Weight,9.92,1.21,-0.352,0.1283862025606869,Terminated,Has Results,Not met / not primary / not significant,0
NCT76449297,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,21,2,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.62,1.32,-0.619,0.0010535108167304408,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82392481,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,15,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,FPG change,8.72,1.01,-1.283,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT48887190,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,118,28,2,GLP-1RA,Placebo,Double,Non-Randomized,Single Group,Industry,Asia,Composite,8.26,1.81,-0.985,2.809461819119896e-05,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT52064343,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,174,13,4,SGLT2i,StandardOfCare,Single,Randomized,Parallel,Academic,Multi-Region,Weight,8.73,0.8,-0.5,4.484101978619037e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT67087104,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,21,4,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Industry,Asia,HbA1c change,7.34,0.97,-0.324,0.07969267478113684,Terminated,Has Results,Not met / not primary / not significant,0
NCT80628709,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,22,6,GLP-1RA,Active,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.81,1.33,-1.403,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86228158,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,158,13,3,Other,StandardOfCare,Double,Randomized,Parallel,Academic,Europe,Composite,8.47,1.29,,,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT11605310,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,12,5,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,6.81,1.22,-0.632,0.00048032085131066715,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT69720522,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,20,2,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.19,1.27,-0.754,4.601142118865198e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19822959,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,19,4,Other,DoseComparison,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.15,0.6,-0.611,2.9976021664879227e-15,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35913857,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,8,3,DPP-4i,Active,Open Label,Randomized,Parallel,Industry,North America,CGM TIR,8.19,1.5,-0.026,0.89576420579017,Completed,Has Results,Not met / not primary / not significant,0
NCT84648574,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,9,2,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Asia,HbA1c change,8.01,1.05,-0.671,2.7452636996994073e-07,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT32546185,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,4,3,TZD,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.7,1.41,-0.575,0.0011239555527867706,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81713537,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,20,2,TZD,Placebo,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,7.12,0.6,-0.964,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51670701,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,155,14,2,DPP-4i,Active,Double,Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.5,1.16,-0.676,3.150517755567961e-07,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT30937666,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,168,15,3,TZD,StandardOfCare,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.19,0.96,-1.029,0.0,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40081977,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,6,3,Other,Active,Open Label,Randomized,Parallel,Industry,North America,Weight,7.44,1.24,-0.093,0.5816099300360464,Completed,Has Results,Not met / not primary / not significant,0
NCT57769262,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,51,9,3,DPP-4i,Placebo,Single,Randomized,Parallel,Industry,Asia,FPG change,8.44,1.18,-0.613,0.008616533277743699,Completed,Has Results,Not met / not primary / not significant,0
NCT78863244,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,13,3,SGLT2i,Placebo,Double,Randomized,Parallel,Government,Europe,Composite,8.19,1.19,-1.118,1.2769507673482394e-10,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT64541423,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,12,5,DPP-4i,Placebo,Double,Randomized,Single Group,Government,North America,Weight,8.08,0.84,-0.439,0.0001026339050592684,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT93990145,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,59,17,4,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,6.89,1.09,-0.712,0.0003688583165945003,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT88096504,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,20,4,GLP-1RA,Placebo,Double,Randomized,Parallel,Academic,North America,FPG change,8.88,1.05,-1.077,2.798927756231251e-11,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT77801817,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,30,2,GLP-1RA,Active,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.54,1.22,,,Completed,Has Results,Not met / not primary / not significant,0
NCT64279643,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,16,6,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Other,Multi-Region,Composite,8.44,1.35,-0.867,1.8941028945285154e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT36087023,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,107,23,2,SGLT2i,StandardOfCare,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,7.83,1.14,-0.516,0.0009138248841930041,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT47131440,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,47,11,3,Other,DoseComparison,Double,Randomized,Crossover,Industry,North America,FPG change,8.13,0.78,-0.26,0.10710877662643148,Completed,Has Results,Not met / not primary / not significant,0
NCT20700485,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,117,6,3,SGLT2i,Placebo,Open Label,Randomized,Crossover,Industry,Asia,Weight,9.21,1.13,-0.51,0.0005312003665223219,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT43676563,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,14,2,GLP-1RA,Active,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.77,1.75,-1.133,6.737698295511407e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93382500,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,6,3,NovelSmallMolecule,Active,Double,Randomized,Parallel,Academic,Multi-Region,Weight,9.19,1.51,-0.371,0.05156853766713365,Completed,Has Results,Not met / not primary / not significant,0
NCT48329387,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,16,3,Other,Placebo,Double,Non-Randomized,Parallel,Industry,North America,HbA1c change,8.63,0.6,-0.462,6.980501447984011e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT20235593,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,69,11,4,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.68,1.12,-0.615,0.0012056884951758828,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT68673791,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,4,3,SGLT2i,StandardOfCare,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.15,1.33,-0.66,0.003410489654157023,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT96635337,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,26,2,SGLT2i,DoseComparison,Double,Randomized,Parallel,Government,Multi-Region,HbA1c change,8.18,1.05,-1.215,6.13398221105399e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT88074155,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,13,2,Insulin,Active,Double,Randomized,Single Group,Academic,North America,HbA1c change,8.24,0.98,-1.253,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT34666880,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,6,6,DPP-4i,DoseComparison,Open Label,Non-Randomized,Parallel,Industry,Multi-Region,Weight,9.26,1.03,-0.613,1.5712334033302078e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT50850718,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,21,2,SGLT2i,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.05,1.24,-0.935,3.4836405515825675e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57791485,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,12,3,GLP-1RA,Placebo,Triple,Randomized,Parallel,Industry,North America,HbA1c change,8.59,0.81,-1.126,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT32305560,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,23,3,DPP-4i,Active,Double,Non-Randomized,Parallel,Government,Multi-Region,Weight,8.56,1.4,-0.407,0.057328805305682184,Completed,Has Results,Not met / not primary / not significant,0
NCT34182278,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,308,12,2,Other,Placebo,Single,Randomized,Single Group,Academic,Asia,CGM TIR,9.21,1.09,-0.861,0.0,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT31299612,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,13,4,TZD,DoseComparison,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.31,0.87,-0.246,0.09275637442716267,Completed,Has Results,Not met / not primary / not significant,0
NCT99512315,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,18,2,DPP-4i,Placebo,Triple,Randomized,Parallel,Government,Multi-Region,Composite,8.98,1.38,-0.712,0.0013763732629363812,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT77141284,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,438,20,2,GLP-1RA,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.21,0.71,-0.636,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT85677072,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,21,3,SGLT2i,StandardOfCare,Double,Randomized,Single Group,Academic,North America,HbA1c change,7.27,0.96,-0.885,9.928724509222775e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT83491187,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,15,4,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,6.8,0.96,-0.364,0.050133166107333205,Completed,Has Results,Not met / not primary / not significant,0
NCT96322910,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,145,19,3,NovelSmallMolecule,StandardOfCare,Double,Non-Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.95,1.64,-1.054,4.133859821120467e-08,Terminated,Has Results,Not met / not primary / not significant,0
NCT19475027,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,20,4,NovelSmallMolecule,Placebo,Double,Non-Randomized,Crossover,Industry,Asia,HbA1c change,8.87,0.93,-0.352,0.029371090652131726,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT89346918,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,150,17,2,Other,DoseComparison,Open Label,Randomized,Crossover,Industry,Other,HbA1c change,9.03,0.6,-0.107,0.12090372817548967,Completed,Has Results,Not met / not primary / not significant,0
NCT15990297,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,15,3,Other,StandardOfCare,Open Label,Randomized,Parallel,Other,Asia,CGM TIR,7.93,0.95,-0.229,0.10823458155467158,Completed,Has Results,Not met / not primary / not significant,0
NCT52787890,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,7,3,Other,Placebo,Open Label,Randomized,Crossover,Industry,North America,HbA1c change,8.01,1.21,-0.245,0.19631712694814585,Completed,Has Results,Not met / not primary / not significant,0
NCT63499029,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,205,20,6,Other,StandardOfCare,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.32,1.3,-0.505,8.062319899793113e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42207497,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,16,6,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Academic,Multi-Region,FPG change,9.41,1.67,-0.873,2.8648617249937836e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT23155591,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,154,14,4,GLP-1RA,Active,Open Label,Randomized,Single Group,Academic,Other,FPG change,9.59,1.45,-1.192,5.881961584464079e-13,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT27307119,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,121,24,5,SGLT2i,Active,Double,Randomized,Parallel,Other,North America,HbA1c change,8.96,1.15,-0.688,3.0296289025288914e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84219776,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,7,2,Insulin,StandardOfCare,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.63,0.88,-0.809,4.454006385934406e-09,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38685150,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,26,2,GLP-1RA,Placebo,Open Label,Randomized,Single Group,Industry,Multi-Region,Composite,9.33,1.51,-1.031,3.015738936351653e-08,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT37930120,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,171,16,4,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.22,1.01,-0.576,1.2681215644239074e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93102567,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,18,2,TZD,Active,Double,Randomized,Single Group,Industry,North America,HbA1c change,8.13,0.94,-0.394,0.002185394005432273,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22948473,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,224,14,6,Insulin,Active,Double,Randomized,Parallel,Government,Multi-Region,HbA1c change,8.31,1.0,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT92374021,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,146,6,2,GLP-1RA,Placebo,Triple,Randomized,Single Group,Industry,Multi-Region,HbA1c change,7.71,0.79,-0.919,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT92887341,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,15,5,SGLT2i,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,Composite,8.28,0.98,-0.596,7.797558687849815e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT63870367,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,111,18,2,GLP-1RA,Placebo,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,7.62,1.04,-1.147,2.220446049250313e-16,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24897854,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,20,5,NovelSmallMolecule,StandardOfCare,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,9.12,1.28,-0.872,7.493275642200814e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24027477,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,15,3,TZD,Placebo,Double,Randomized,Crossover,Academic,Multi-Region,HbA1c change,8.78,1.0,-0.759,5.37376535920675e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35624807,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,4,4,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,North America,HbA1c change,9.4,0.78,-0.415,0.000245153936479392,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT61967407,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,110,7,3,SGLT2i,DoseComparison,Double,Non-Randomized,Parallel,Academic,North America,HbA1c change,7.26,0.7,-0.255,0.0068359021082184945,Completed,Has Results,Not met / not primary / not significant,0
NCT23825205,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,28,4,DPP-4i,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,Composite,9.73,1.15,-0.769,1.9378478979703573e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT51009213,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,9,3,DPP-4i,Active,Double,Randomized,Parallel,Academic,Asia,FPG change,7.3,1.12,-0.524,0.0003578451336621047,Completed,Has Results,Not met / not primary / not significant,0
NCT20394105,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,25,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.56,0.96,-0.893,5.1651682930753395e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT58625570,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,141,10,3,NovelSmallMolecule,StandardOfCare,Triple,Randomized,Parallel,Academic,North America,HbA1c change,7.97,0.98,-0.672,9.379941157128258e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11903321,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,134,15,3,SGLT2i,Active,Double,Randomized,Parallel,Industry,Other,HbA1c change,9.32,1.2,-0.658,6.771576626651843e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT14985586,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,107,20,6,Other,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.56,1.45,-0.952,1.526154421949144e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT27533965,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,11,4,GLP-1RA,Placebo,Double,Randomized,Single Group,Academic,Asia,HbA1c change,8.23,0.9,-0.969,2.6327113489266196e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25717732,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,223,26,3,Other,Placebo,Open Label,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.85,1.12,-0.515,1.236288208139591e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84789467,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,93,16,2,GLP-1RA,StandardOfCare,Double,Randomized,Crossover,Industry,Europe,CGM TIR,7.44,1.34,-0.851,1.4676514083045156e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT14804373,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,19,4,SGLT2i,Placebo,Double,Randomized,Parallel,Government,Multi-Region,Weight,9.19,0.91,-1.016,7.993605777301127e-15,Completed,Has Results,Not met / not primary / not significant,0
NCT48633369,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,14,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.96,1.1,-1.068,2.1645252257229686e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63202942,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,20,2,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Multi-Region,Weight,9.35,1.09,-1.441,1.1102230246251565e-16,Completed,Has Results,Not met / not primary / not significant,0
NCT56439599,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,199,25,2,DPP-4i,DoseComparison,Open Label,Randomized,Parallel,Other,Multi-Region,HbA1c change,8.68,0.77,-0.378,1.0759093713730294e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71264306,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,186,15,2,DPP-4i,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,6.55,1.14,-0.838,1.520672476829077e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82279117,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,122,26,3,SGLT2i,Active,Double,Randomized,Parallel,Academic,North America,Weight,7.53,1.11,-0.412,0.003649669626826557,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT45426740,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,12,2,NovelSmallMolecule,Active,Triple,Randomized,Parallel,Industry,North America,HbA1c change,8.73,1.24,-0.259,0.14937035053092595,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT84539607,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,21,4,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Academic,Other,HbA1c change,8.14,0.8,-0.569,9.969652658980976e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38619198,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,19,4,NovelSmallMolecule,Placebo,Single,Randomized,Parallel,Academic,Other,FPG change,8.01,1.1,-0.455,0.0030632847268385888,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT98598043,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,10,2,SGLT2i,Placebo,Single,Randomized,Parallel,Academic,Other,HbA1c change,7.63,1.45,-0.626,0.0035109183656319987,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55407360,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,116,17,3,Insulin,Active,Double,Randomized,Parallel,Industry,North America,Weight,9.06,1.62,-1.107,1.9088097202857313e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT76241199,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,16,3,SGLT2i,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,8.72,1.42,-1.333,1.8449629601846596e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT88750443,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,111,11,2,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,CGM TIR,8.75,0.81,-0.913,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT81338611,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,18,5,GLP-1RA,StandardOfCare,Triple,Randomized,Parallel,Other,Multi-Region,HbA1c change,7.96,1.21,-0.855,1.9457914557374778e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86601845,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,130,17,3,Other,Placebo,Single,Randomized,Parallel,Industry,North America,HbA1c change,8.52,0.98,-0.456,0.00017610434002635067,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT58286221,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,75,16,4,Other,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.46,1.17,-0.433,0.023695456056409436,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT13912755,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,137,16,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Single Group,Government,North America,Weight,8.31,0.91,-1.041,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT54377517,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,15,3,Insulin,DoseComparison,Single,Randomized,Parallel,Industry,Asia,HbA1c change,6.63,0.67,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT26334856,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,14,5,DPP-4i,DoseComparison,Double,Randomized,Parallel,Industry,North America,Weight,7.3,1.01,-0.194,0.23577789722899234,Completed,Has Results,Not met / not primary / not significant,0
NCT90020491,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,17,4,Insulin,DoseComparison,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,8.17,1.28,-0.991,1.3422118153583185e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT31307038,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,61,12,3,Insulin,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,10.06,1.17,-1.704,9.992007221626409e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30526284,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,157,32,5,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.14,1.2,-0.767,1.4903874467897538e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT32444881,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,8,2,GLP-1RA,Placebo,Double,Randomized,Single Group,Industry,Multi-Region,HbA1c change,7.53,1.15,-1.461,8.113509863960644e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67830962,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,73,12,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,Composite,8.55,1.2,-0.956,1.5350479272147055e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT61410938,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,175,13,2,Other,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,9.64,1.23,-0.527,6.314021800679637e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT95395677,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,28,3,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Europe,FPG change,8.54,1.03,-0.769,3.765759736595875e-06,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT47463617,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,8,3,Other,DoseComparison,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,8.89,1.12,-0.75,6.397138297087324e-06,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT35405034,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,19,3,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,8.16,1.54,-0.863,0.0016035364456398193,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT14432870,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,145,17,2,Insulin,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.04,1.14,-1.46,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT10636831,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,146,18,6,SGLT2i,StandardOfCare,Triple,Randomized,Parallel,Academic,Multi-Region,Weight,8.46,1.11,-0.426,0.001040072424720373,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT43625272,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,139,23,4,SGLT2i,Active,Open Label,Randomized,Single Group,Academic,Multi-Region,FPG change,7.94,1.13,-0.445,0.000990612790315093,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT93323564,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,127,23,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.91,1.05,-1.359,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57137764,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,13,2,GLP-1RA,Active,Double,Randomized,Single Group,Industry,North America,FPG change,7.28,0.99,-1.14,1.1102230246251565e-16,Completed,Has Results,Not met / not primary / not significant,0
NCT90419284,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,79,17,2,Other,StandardOfCare,Double,Randomized,Parallel,Government,Asia,HbA1c change,9.02,1.15,-1.034,1.681573724710006e-08,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19150471,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,69,5,5,SGLT2i,Active,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.43,0.97,-0.665,5.978518329452509e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18398890,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,178,17,2,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,FPG change,8.25,1.06,-1.159,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT19606782,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,11,6,DPP-4i,Active,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.25,0.9,-0.468,1.4471775755864336e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT14676567,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,73,15,2,DPP-4i,Placebo,Double,Non-Randomized,Single Group,Industry,Asia,CGM TIR,7.71,1.13,-0.529,0.004585801009348245,Completed,Has Results,Not met / not primary / not significant,0
NCT46368341,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,6,2,Insulin,Placebo,Open Label,Randomized,Parallel,Academic,Multi-Region,Composite,9.24,1.25,-1.175,2.0917823029265037e-11,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT93235767,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,18,4,SGLT2i,Placebo,Triple,Non-Randomized,Single Group,Other,North America,Composite,8.25,1.05,-0.284,0.07354693760188058,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT72044503,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,6,3,Other,Placebo,Open Label,Randomized,Parallel,Other,Other,CGM TIR,8.59,0.6,-0.497,5.585926553086651e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT18920182,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,17,3,NovelSmallMolecule,StandardOfCare,Double,Randomized,Parallel,Industry,Other,HbA1c change,7.78,1.25,-0.756,8.482330518977399e-06,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT85341793,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,9,3,NovelSmallMolecule,Placebo,Open Label,Non-Randomized,Parallel,Industry,Europe,CGM TIR,8.38,1.13,-0.328,0.06111452488844993,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT85921744,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,65,11,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.44,0.85,-0.448,0.002735463360303836,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82062687,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,51,23,3,GLP-1RA,Placebo,Open Label,Randomized,Single Group,Industry,North America,HbA1c change,8.47,1.29,-1.062,3.380721521151209e-05,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT91238782,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,49,20,2,Other,StandardOfCare,Double,Randomized,Crossover,Industry,Multi-Region,HbA1c change,8.66,0.75,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT31589021,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,23,6,SGLT2i,Placebo,Single,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.62,1.36,-1.497,1.0380585280245214e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT98161360,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,25,5,GLP-1RA,Active,Open Label,Non-Randomized,Parallel,Industry,Multi-Region,Composite,7.77,1.09,-0.243,0.12066500137448988,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT38862667,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,67,11,2,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Other,Multi-Region,Weight,8.16,0.6,-0.633,9.925592570070307e-10,Completed,Has Results,Not met / not primary / not significant,0
NCT82182328,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,133,25,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.78,1.14,-1.047,8.615330671091215e-14,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62142809,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,97,7,3,TZD,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.25,1.0,-0.546,0.00013893416823751448,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT80152977,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,20,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Government,Asia,FPG change,8.2,0.96,-0.705,3.764712874776421e-09,Completed,Has Results,Not met / not primary / not significant,0
NCT66503747,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,13,3,NovelSmallMolecule,Placebo,Double,Non-Randomized,Parallel,Academic,North America,HbA1c change,9.73,0.92,-0.784,6.393995444220479e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67823494,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,10,2,SGLT2i,Active,Open Label,Randomized,Crossover,Industry,North America,CGM TIR,7.73,1.07,-0.346,0.05538469198702167,Completed,Has Results,Not met / not primary / not significant,0
NCT65465567,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,20,2,Other,DoseComparison,Single,Randomized,Parallel,Industry,Multi-Region,Composite,9.16,0.98,-0.34,0.011910430807692829,Recruiting,Has Results,Not met / not primary / not significant,0
NCT80109671,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,56,22,6,DPP-4i,Placebo,Triple,Non-Randomized,Parallel,Industry,Asia,HbA1c change,7.59,0.64,-0.453,0.00016589493015106704,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76513865,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,127,21,4,TZD,Active,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,8.86,1.42,-1.637,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22109698,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,65,17,2,GLP-1RA,Placebo,Double,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.9,1.04,-0.838,4.2458600458816775e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT84344938,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,150,17,4,Other,Active,Triple,Randomized,Parallel,Industry,Asia,HbA1c change,8.04,0.92,-0.466,1.056075521288502e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT58246122,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,19,6,SGLT2i,Active,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,7.55,0.82,-0.693,3.337930110092202e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT39077507,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,160,18,5,GLP-1RA,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,7.02,1.29,-0.644,8.31259847411392e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56280057,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,19,2,DPP-4i,Active,Double,Randomized,Crossover,Academic,Asia,HbA1c change,7.97,0.78,-0.587,3.335207656374184e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT97028511,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,73,17,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.77,1.13,-1.066,1.3167416268444754e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT87181492,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,118,21,2,GLP-1RA,Active,Double,Non-Randomized,Parallel,Industry,Asia,HbA1c change,7.65,0.95,-0.754,1.2469241195134373e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT85032865,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,168,6,6,TZD,Active,Open Label,Randomized,Parallel,Industry,Asia,FPG change,8.47,0.97,-0.735,3.567146578120628e-12,Completed,Has Results,Not met / not primary / not significant,0
NCT51651942,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,211,15,5,DPP-4i,Active,Open Label,Randomized,Crossover,Industry,Multi-Region,HbA1c change,7.37,0.82,-0.232,0.003862006223342651,Completed,Has Results,Not met / not primary / not significant,0
NCT80572405,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,8,3,Other,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,Weight,8.24,0.94,-0.544,4.279814141039395e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT44658054,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,227,18,2,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.6,1.1,-0.439,2.1561516257206925e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71754892,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,26,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.35,1.16,-0.435,0.01333919059360078,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67560693,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,163,13,4,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.05,0.9,-0.45,6.87844758462397e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT32481883,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,65,17,2,TZD,Placebo,Double,Randomized,Parallel,Industry,Asia,FPG change,7.57,1.08,-1.05,2.7762614873694247e-08,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT33981698,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,21,3,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.94,1.32,-0.685,5.9720346265002e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT15501982,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,35,4,6,DPP-4i,Active,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.75,0.68,-0.668,4.4330573569340004e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22579156,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,13,5,Other,Placebo,Double,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.48,1.1,-0.092,0.6451944622853624,Completed,Has Results,Not met / not primary / not significant,0
NCT49025678,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,18,3,SGLT2i,StandardOfCare,Single,Randomized,Parallel,Industry,Asia,Composite,9.16,0.86,-1.147,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT53008954,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,4,4,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.15,0.84,-1.382,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT24860865,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,121,10,5,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Industry,Europe,HbA1c change,6.86,1.17,0.114,0.4462761930201965,Completed,Has Results,Not met / not primary / not significant,0
NCT47520042,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,150,23,3,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,Weight,7.96,0.96,,,Completed,Has Results,Not met / not primary / not significant,0
NCT64375976,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,79,22,2,GLP-1RA,Placebo,Double,Randomized,Single Group,Industry,Europe,HbA1c change,9.04,0.8,-1.131,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT30931294,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,18,3,DPP-4i,Active,Triple,Randomized,Parallel,Industry,Europe,HbA1c change,7.87,1.43,-0.881,0.0004948123549365357,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40441320,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,21,4,Other,DoseComparison,Double,Randomized,Parallel,Other,Asia,CGM TIR,9.45,1.33,-0.436,0.038214500665098905,Completed,Has Results,Not met / not primary / not significant,0
NCT43076062,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,17,2,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.8,0.62,-0.599,3.9839097354388286e-08,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55454849,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,19,4,Other,Placebo,Open Label,Randomized,Parallel,Government,Multi-Region,HbA1c change,8.75,0.73,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42975320,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,104,14,2,Insulin,Active,Triple,Randomized,Parallel,Academic,North America,HbA1c change,9.13,1.25,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76325014,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,17,3,TZD,Active,Double,Randomized,Parallel,Academic,Europe,HbA1c change,8.72,1.03,-0.969,5.312008610758312e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT39474600,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,211,12,5,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,North America,Weight,7.44,1.48,-0.696,1.2404038099989023e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT49050707,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,24,2,Other,Placebo,Double,Randomized,Parallel,Industry,Asia,FPG change,7.74,1.25,-0.791,0.0001551600634925876,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT44151766,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,186,25,6,DPP-4i,Placebo,Single,Randomized,Parallel,Industry,North America,HbA1c change,9.22,1.17,-0.928,2.531308496145357e-14,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT26462421,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,24,2,NovelSmallMolecule,DoseComparison,Single,Non-Randomized,Parallel,Industry,Asia,HbA1c change,7.84,0.84,-0.459,0.002486673358696012,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71716900,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,14,5,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,FPG change,9.08,1.22,-0.584,0.0006155700646894857,Completed,Has Results,Not met / not primary / not significant,0
NCT31190154,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,169,10,3,Insulin,Placebo,Open Label,Randomized,Single Group,Industry,Asia,FPG change,8.1,0.78,-1.195,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT36718882,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,166,24,3,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Government,North America,HbA1c change,8.5,1.43,-0.949,1.3660731434939066e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81347675,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,19,3,Insulin,Placebo,Double,Non-Randomized,Parallel,Industry,Europe,Weight,7.43,1.21,-0.599,0.0014665578989238037,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT95397212,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,18,2,Other,Placebo,Double,Randomized,Crossover,Industry,Asia,HbA1c change,7.97,0.89,-0.397,0.00038351991373808403,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70375883,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,120,12,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Asia,CGM TIR,7.79,1.3,-0.219,0.1915265024221936,Completed,Has Results,Not met / not primary / not significant,0
NCT92471320,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,78,19,4,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.56,1.66,-0.635,0.017004225692176078,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86877156,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,9,2,SGLT2i,Placebo,Double,Randomized,Parallel,Government,Multi-Region,HbA1c change,8.47,1.05,-0.408,0.0015818676876828697,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53281938,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,230,20,3,DPP-4i,Placebo,Open Label,Randomized,Single Group,Industry,Asia,FPG change,8.72,1.24,-0.557,1.4202696402287884e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT79326115,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,24,3,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Government,Europe,CGM TIR,8.06,0.99,-0.302,0.01701103430028572,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT39552508,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,26,2,GLP-1RA,Active,Open Label,Randomized,Parallel,Academic,North America,HbA1c change,7.75,1.12,-0.449,0.0013668413874439178,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT51444734,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,20,4,GLP-1RA,Placebo,Double,Randomized,Crossover,Industry,Europe,HbA1c change,8.53,0.72,-1.099,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT58189130,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,8,3,NovelSmallMolecule,Active,Double,Randomized,Crossover,Industry,Europe,CGM TIR,7.68,1.1,-0.776,0.00032242266827242627,Completed,Has Results,Not met / not primary / not significant,0
NCT96444370,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,122,17,3,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.15,1.11,-0.926,7.327427553605048e-11,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86370443,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,29,4,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.32,1.55,-0.443,0.10891918936044331,Completed,Has Results,Not met / not primary / not significant,0
NCT54032766,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,11,5,GLP-1RA,Placebo,Single,Randomized,Parallel,Industry,Europe,FPG change,8.17,0.65,-1.093,0.0,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT68732859,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,263,16,2,SGLT2i,Active,Double,Randomized,Parallel,Other,Multi-Region,HbA1c change,8.72,1.03,-0.55,9.214785601230346e-10,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT28212084,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,24,2,SGLT2i,Placebo,Double,Randomized,Single Group,Industry,Other,HbA1c change,8.35,1.42,-0.707,0.0009052123610653329,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT82395263,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,20,4,NovelSmallMolecule,Active,Double,Randomized,Parallel,Academic,North America,HbA1c change,7.24,1.04,-0.533,0.0022728654898875877,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59773415,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,167,31,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,Weight,7.66,1.06,-0.666,8.703818776822914e-09,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT57945004,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,65,12,3,SGLT2i,StandardOfCare,Double,Randomized,Crossover,Other,Multi-Region,HbA1c change,9.14,0.89,-0.736,2.5137969733579624e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78965516,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,10,5,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Industry,Other,FPG change,8.46,0.87,-0.705,2.2573529057101638e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT66962585,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,175,23,4,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,Multi-Region,Composite,7.22,0.64,-0.916,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT16522037,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,101,9,2,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,North America,FPG change,8.65,0.94,-0.759,1.0605971767496669e-08,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT35934004,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,49,15,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.01,0.85,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25904706,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,127,16,5,SGLT2i,StandardOfCare,Double,Non-Randomized,Crossover,Academic,North America,HbA1c change,7.79,1.13,-0.502,0.00040263734097334414,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76140383,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,22,3,NovelSmallMolecule,DoseComparison,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.6,0.9,-0.722,2.6096606398073874e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT13163245,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,199,20,3,Other,Placebo,Double,Non-Randomized,Parallel,Industry,Asia,HbA1c change,9.1,0.98,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT28216413,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,19,4,SGLT2i,Placebo,Double,Non-Randomized,Parallel,Industry,Asia,Composite,7.02,0.99,-0.664,3.330176617377667e-05,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT63770052,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,160,14,2,Insulin,Placebo,Open Label,Randomized,Single Group,Industry,Asia,CGM TIR,7.81,1.09,-1.101,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT72531830,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,221,23,4,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.48,0.97,-0.592,1.2572576313374384e-10,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT55297440,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,40,6,Other,Active,Double,Randomized,Single Group,Industry,Asia,HbA1c change,9.5,0.83,-0.759,1.1477789818581385e-07,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT87464715,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,20,4,TZD,DoseComparison,Double,Randomized,Single Group,Industry,North America,Weight,8.79,1.12,-0.792,1.8733998190523238e-06,Completed,Has Results,Not met / not primary / not significant,0
NCT92704606,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,118,17,2,SGLT2i,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.81,1.37,-0.318,0.07352015367388187,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT21889255,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,8,4,TZD,Placebo,Open Label,Randomized,Crossover,Industry,Multi-Region,Weight,9.47,1.13,,,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT95725997,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,112,12,2,SGLT2i,Active,Double,Randomized,Parallel,Other,Asia,HbA1c change,7.45,0.95,-0.034,0.7866935654561008,Terminated,Has Results,Not met / not primary / not significant,0
NCT67259723,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,15,4,Other,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,FPG change,8.59,1.07,-0.935,4.3890812095881415e-09,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT18558617,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,13,3,DPP-4i,DoseComparison,Double,Randomized,Parallel,Academic,Multi-Region,CGM TIR,8.74,0.6,-0.76,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT65968468,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,16,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Crossover,Industry,Multi-Region,HbA1c change,7.78,1.07,-0.813,4.930263119984346e-08,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75314405,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,27,6,GLP-1RA,Placebo,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.89,1.0,-0.75,7.280761848971196e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62271201,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,107,23,6,DPP-4i,StandardOfCare,Double,Non-Randomized,Crossover,Industry,North America,Weight,8.04,0.87,-0.587,7.108588366833146e-07,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT17604389,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,76,15,3,NovelSmallMolecule,Placebo,Double,Randomized,Single Group,Industry,Asia,HbA1c change,8.89,0.91,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57090470,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,9,3,TZD,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.11,1.0,-0.698,1.4198652723340643e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT94234583,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,94,24,4,DPP-4i,DoseComparison,Double,Randomized,Crossover,Industry,North America,HbA1c change,8.63,1.35,-0.778,7.561630466301761e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75107485,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,16,4,Other,DoseComparison,Double,Randomized,Single Group,Industry,North America,HbA1c change,8.11,1.37,,,Completed,Has Results,Not met / not primary / not significant,0
NCT22366713,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,6,4,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Other,North America,FPG change,9.2,0.87,-0.566,3.0030366696132127e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT96394464,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,115,20,4,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.37,0.97,-0.507,7.479294671897119e-05,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT96299221,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,44,22,3,Insulin,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,9.27,0.98,,,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25245597,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,4,4,DPP-4i,Placebo,Double,Non-Randomized,Single Group,Industry,North America,Weight,8.76,1.3,-0.452,0.037237620342759015,Completed,Has Results,Not met / not primary / not significant,0
NCT82079575,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,11,5,TZD,Placebo,Double,Non-Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.31,1.14,-1.123,5.526767932195753e-11,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT46604539,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,68,15,3,SGLT2i,Active,Single,Randomized,Parallel,Academic,North America,HbA1c change,8.95,1.12,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63431379,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,207,20,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Europe,FPG change,8.96,1.23,-0.493,4.811056414300019e-05,Recruiting,Has Results,Not met / not primary / not significant,0
NCT50066767,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,13,5,Other,Active,Double,Randomized,Parallel,Industry,North America,Weight,8.73,0.95,0.065,0.6273572053203065,Completed,Has Results,Not met / not primary / not significant,0
NCT80436168,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,11,5,Other,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,6.8,1.44,-0.028,0.888142042372951,Completed,Has Results,Not met / not primary / not significant,0
NCT99699386,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,20,2,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,Other,CGM TIR,7.71,1.1,-1.037,2.4828531453024993e-09,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT81560334,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,99,13,4,Other,Placebo,Single,Randomized,Single Group,Other,Asia,HbA1c change,9.37,0.89,-0.946,5.850875339774575e-14,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT93823427,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,58,19,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.52,1.04,-0.984,3.678129452122647e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT95142434,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,9,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Single Group,Academic,North America,Composite,9.02,1.41,-0.559,0.007098708298621803,Completed,Has Results,Not met / not primary / not significant,0
NCT18109488,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,65,8,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,Weight,8.89,0.99,-0.287,0.09964497270162287,Completed,Has Results,Not met / not primary / not significant,0
NCT32804501,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,21,2,DPP-4i,StandardOfCare,Single,Randomized,Single Group,Other,Multi-Region,HbA1c change,7.89,1.34,-0.735,0.0002653787088937598,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74967090,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,31,18,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.0,0.94,-0.687,0.004169272735801477,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT63106829,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,60,22,6,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Other,HbA1c change,8.0,0.91,-0.536,0.0012391516251359924,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT14513155,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,192,13,5,TZD,StandardOfCare,Double,Randomized,Parallel,Academic,Asia,HbA1c change,9.85,1.26,-1.453,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18554427,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,145,11,3,SGLT2i,Active,Double,Randomized,Parallel,Industry,Asia,Weight,7.8,0.88,-0.559,6.665646012926629e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT56849264,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,180,24,3,SGLT2i,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,CGM TIR,7.84,1.31,-0.879,1.7296553078693933e-10,Recruiting,Has Results,Not met / not primary / not significant,0
NCT65454912,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,186,7,5,TZD,Placebo,Double,Randomized,Crossover,Other,North America,HbA1c change,7.7,1.19,-0.81,4.867084513193731e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25094740,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,24,5,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.25,0.88,-0.736,6.983635891799622e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT25416217,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,24,2,SGLT2i,Active,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.23,1.08,-0.838,8.186970987811293e-07,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21640619,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,21,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Academic,Multi-Region,HbA1c change,7.96,0.96,-0.461,0.0076497873446340625,Recruiting,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT60845554,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,167,12,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Academic,Asia,FPG change,9.39,1.19,-0.892,6.72184530259301e-12,Completed,Has Results,Not met / not primary / not significant,0
NCT10706827,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,11,5,GLP-1RA,Placebo,Double,Randomized,Parallel,Government,North America,HbA1c change,8.81,1.57,-1.001,5.402911314011938e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT61518745,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,306,15,6,GLP-1RA,Active,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.76,1.01,-0.773,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT52833579,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,84,8,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,North America,FPG change,7.54,1.23,-0.756,7.093561691173811e-05,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT51938663,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,242,10,4,NovelSmallMolecule,StandardOfCare,Double,Randomized,Single Group,Industry,North America,Composite,9.21,1.11,,,Completed,Has Results,Not met / not primary / not significant,0
NCT71134862,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,93,20,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.41,1.11,-0.786,1.2766617514259337e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT57036859,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,181,20,5,GLP-1RA,Active,Double,Randomized,Parallel,Academic,Europe,HbA1c change,7.32,1.06,-0.879,2.886579864025407e-15,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75497387,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,213,10,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.15,0.89,-0.716,1.1102230246251565e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT78753104,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,63,20,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,7.62,1.18,-1.287,1.0517914317276222e-09,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT92810596,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,19,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,7.53,1.03,-0.02,0.9000838711910166,Recruiting,Has Results,Not met / not primary / not significant,0
NCT81932023,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,25,3,Other,StandardOfCare,Open Label,Randomized,Single Group,Industry,North America,HbA1c change,6.97,0.87,-0.615,8.989004909565335e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56593556,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,19,6,SGLT2i,StandardOfCare,Double,Randomized,Parallel,Academic,North America,HbA1c change,7.63,1.35,-0.885,0.00048554020467928005,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT54293788,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,134,22,6,GLP-1RA,Placebo,Triple,Non-Randomized,Parallel,Industry,Other,HbA1c change,7.76,1.12,-0.757,3.625571409759942e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT31213772,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,19,6,DPP-4i,Placebo,Open Label,Randomized,Crossover,Industry,North America,Weight,8.08,1.04,-0.599,0.00010699091233268287,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT63963409,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,22,2,TZD,DoseComparison,Open Label,Non-Randomized,Parallel,Academic,Asia,HbA1c change,9.59,1.44,-0.667,0.0009074614076062248,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22522189,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,128,8,3,Other,Placebo,Open Label,Non-Randomized,Crossover,Other,North America,FPG change,8.21,0.64,-0.344,1.785426036360338e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT93811260,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,43,15,6,Other,Placebo,Double,Non-Randomized,Parallel,Industry,North America,FPG change,8.28,1.42,0.031,0.9180441870385412,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT86053982,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,178,16,2,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Other,Asia,CGM TIR,8.76,0.88,-1.057,0.0,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT20776022,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,15,2,GLP-1RA,Active,Double,Randomized,Single Group,Industry,Multi-Region,FPG change,8.23,1.15,-0.778,1.0745443111082054e-05,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT80736028,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,126,19,6,NovelSmallMolecule,Active,Triple,Randomized,Crossover,Academic,Multi-Region,Weight,8.68,0.95,-0.603,5.020730180493871e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT20539320,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,132,20,2,SGLT2i,Active,Open Label,Randomized,Single Group,Industry,Multi-Region,FPG change,8.6,0.87,,,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT74910266,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,184,18,3,Other,DoseComparison,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.49,1.43,-0.237,0.11078784209835135,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT17893810,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,15,2,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Academic,Europe,HbA1c change,10.34,1.56,-0.509,0.02479881210457857,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53937407,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,38,12,2,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,9.04,1.04,-0.379,0.11416408762750552,Completed,Has Results,Not met / not primary / not significant,0
NCT69207694,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,102,23,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.64,1.18,-0.613,0.00021994012087889203,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75592974,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,18,5,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.66,1.11,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT47674746,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,10,4,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,7.85,1.53,,,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT92946111,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,106,15,4,Insulin,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.71,0.6,-1.504,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT79688926,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,85,6,3,Insulin,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.44,1.19,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT28743827,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,16,4,NovelSmallMolecule,Active,Open Label,Randomized,Parallel,Industry,Multi-Region,HbA1c change,7.62,0.92,-0.543,0.0021191070894652775,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT70410826,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,135,15,6,TZD,Placebo,Double,Randomized,Crossover,Other,Multi-Region,CGM TIR,8.64,0.6,-0.897,0.0,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT75748111,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,13,2,Other,Placebo,Double,Randomized,Single Group,Other,North America,HbA1c change,9.1,1.01,-0.78,1.6415430763583316e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT40027397,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,83,26,3,Other,Active,Open Label,Randomized,Parallel,Industry,Other,CGM TIR,8.75,1.56,-0.064,0.7923443459344965,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT76440818,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,81,9,6,Insulin,Active,Single,Randomized,Single Group,Industry,North America,HbA1c change,9.0,0.94,-1.129,1.609823385706477e-14,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT90852988,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,173,20,3,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,Weight,8.66,1.3,-0.555,6.935075185643402e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT83540284,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,98,29,4,NovelSmallMolecule,StandardOfCare,Single,Randomized,Parallel,Industry,North America,CGM TIR,8.52,1.4,-0.396,0.04763538795984079,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT78627892,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,22,4,Other,Active,Single,Randomized,Crossover,Government,North America,HbA1c change,8.05,1.1,-0.458,0.0027420811214337037,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67104768,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,16,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,Composite,8.97,1.13,-0.358,0.042584028762122084,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT34348144,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,123,9,2,DPP-4i,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,9.12,0.67,-0.633,1.3522516439934407e-13,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT81570064,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,183,8,5,DPP-4i,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.36,0.92,-0.65,1.416877726256871e-11,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT42777281,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,133,14,3,GLP-1RA,Placebo,Double,Randomized,Parallel,Industry,Asia,CGM TIR,8.32,1.33,-1.238,2.731148640577885e-14,Completed,Has Results,Not met / not primary / not significant,0
NCT57897713,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,136,12,4,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Government,Multi-Region,HbA1c change,9.51,1.12,-0.985,3.2862601528904634e-13,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38299597,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,131,12,2,SGLT2i,Placebo,Open Label,Randomized,Parallel,Academic,Asia,HbA1c change,8.39,1.19,-0.67,5.316616072281732e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT38171536,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,14,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.45,1.13,-0.4,0.06912059227292622,Completed,Has Results,Not met / not primary / not significant,0
NCT24185048,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,67,15,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,North America,HbA1c change,8.74,1.65,-0.68,0.016862545403946827,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT96516790,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,91,19,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Other,Multi-Region,HbA1c change,8.33,0.99,-0.653,8.94468078338484e-06,"Active, not recruiting",Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT23300503,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,9,3,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.83,1.5,-1.012,5.2652064028380074e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT17763293,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,62,12,3,SGLT2i,DoseComparison,Double,Randomized,Single Group,Academic,North America,HbA1c change,8.66,1.13,-1.009,7.144299418726519e-07,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT94251470,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,43,15,3,NovelSmallMolecule,Placebo,Open Label,Randomized,Crossover,Government,North America,HbA1c change,8.37,1.52,-0.217,0.5083512928579562,Completed,Has Results,Not met / not primary / not significant,0
NCT59951184,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,15,2,NovelSmallMolecule,DoseComparison,Open Label,Non-Randomized,Single Group,Industry,Asia,HbA1c change,9.69,0.79,-0.568,0.00019938665274421563,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49411362,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,89,27,4,DPP-4i,Placebo,Double,Randomized,Parallel,Government,Europe,HbA1c change,8.95,1.15,-0.998,6.213273229249694e-09,Recruiting,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76374220,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,17,2,Other,DoseComparison,Open Label,Randomized,Crossover,Industry,Asia,FPG change,7.98,1.0,-0.383,0.008133514393196872,Recruiting,Has Results,Not met / not primary / not significant,0
NCT44498783,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,70,6,2,GLP-1RA,DoseComparison,Open Label,Randomized,Parallel,Academic,Europe,HbA1c change,8.91,1.13,-0.846,1.031347482882694e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT21512945,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,103,19,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.62,1.41,-0.799,4.523736237305176e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75671713,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,82,19,2,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Europe,CGM TIR,9.32,1.19,-0.778,3.014539788015469e-05,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT25839954,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,163,15,2,GLP-1RA,DoseComparison,Open Label,Randomized,Parallel,Industry,North America,Weight,8.03,1.41,-0.621,6.670904419214807e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT59769375,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,93,9,4,Insulin,DoseComparison,Double,Randomized,Single Group,Industry,Europe,HbA1c change,8.53,0.93,-1.137,1.1102230246251565e-16,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT95415951,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,136,27,4,GLP-1RA,DoseComparison,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.33,0.89,-1.089,0.0,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT94252597,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,10,3,GLP-1RA,Active,Double,Randomized,Single Group,Industry,Asia,CGM TIR,8.44,1.1,-0.785,1.5113046780701467e-07,Completed,Has Results,Not met / not primary / not significant,0
NCT42470468,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,53,20,2,GLP-1RA,Placebo,Double,Non-Randomized,Parallel,Industry,North America,Weight,7.78,1.09,-0.834,8.272055172553472e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT80227133,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,96,17,3,DPP-4i,StandardOfCare,Double,Randomized,Parallel,Industry,Asia,HbA1c change,8.8,1.05,-0.852,2.0686463875208005e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT65140821,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,57,20,4,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.69,0.86,-0.703,1.2840494878596509e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT53143260,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,95,26,4,GLP-1RA,Active,Double,Randomized,Parallel,Other,North America,HbA1c change,9.3,1.4,-1.443,1.2043699371133698e-12,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT22593530,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,19,2,TZD,Placebo,Triple,Randomized,Parallel,Other,North America,HbA1c change,8.39,1.01,-0.929,4.2108770137438967e-08,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT43872352,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,118,13,4,NovelSmallMolecule,Active,Open Label,Non-Randomized,Parallel,Industry,Asia,Weight,8.11,1.46,0.034,0.8588457457844153,Completed,Has Results,Not met / not primary / not significant,0
NCT68672626,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,54,23,4,GLP-1RA,Placebo,Single,Randomized,Single Group,Industry,Europe,FPG change,8.95,1.1,-1.5,1.6039392036759637e-12,Completed,Has Results,Not met / not primary / not significant,0
NCT98796838,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,12,5,GLP-1RA,Active,Open Label,Non-Randomized,Parallel,Academic,Asia,HbA1c change,7.84,1.26,-0.476,0.007645069429477069,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT74598420,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,129,17,3,NovelSmallMolecule,Placebo,Triple,Randomized,Parallel,Academic,North America,FPG change,9.16,1.24,-0.614,7.01587573421758e-05,Recruiting,Has Results,Not met / not primary / not significant,0
NCT86170317,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,150,8,3,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,Multi-Region,CGM TIR,9.16,0.89,-0.563,4.9368686583228794e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT95607518,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,10,2,Insulin,StandardOfCare,Double,Randomized,Parallel,Academic,North America,HbA1c change,9.28,1.19,-1.205,1.7064141211164952e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT48142331,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,100,16,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Asia,CGM TIR,8.66,1.58,-0.902,5.574745468261977e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT20663071,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,108,18,5,GLP-1RA,Placebo,Triple,Randomized,Parallel,Industry,Multi-Region,HbA1c change,8.06,1.16,-1.254,2.220446049250313e-15,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT34387046,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,200,6,4,DPP-4i,Placebo,Open Label,Randomized,Parallel,Academic,Europe,HbA1c change,8.48,1.33,-0.707,9.713375392905732e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT86548030,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,51,19,6,NovelSmallMolecule,DoseComparison,Double,Randomized,Parallel,Academic,North America,HbA1c change,8.67,1.27,-0.62,0.013968406143811452,Terminated,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT89014141,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,11,3,SGLT2i,Active,Double,Randomized,Parallel,Academic,Asia,HbA1c change,8.01,1.18,-0.42,0.04012780480214928,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT67336648,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,351,24,2,NovelSmallMolecule,Placebo,Open Label,Randomized,Parallel,Industry,Other,Composite,9.33,1.15,-0.47,5.5466371495782596e-08,Completed,Has Results,Not met / not primary / not significant,0
NCT21046644,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,88,14,5,Insulin,Placebo,Double,Randomized,Parallel,Industry,Other,HbA1c change,8.81,1.24,-1.116,2.182243385995264e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT20972950,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,42,9,2,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,7.78,1.29,-0.477,0.09066471512941476,Completed,Has Results,Not met / not primary / not significant,0
NCT53035489,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,77,16,2,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.72,0.76,-0.679,3.2599077992578884e-08,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT62943219,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,30,11,2,DPP-4i,DoseComparison,Double,Randomized,Parallel,Industry,Europe,HbA1c change,8.47,1.16,-0.655,0.028904329326552958,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT12914076,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,111,24,3,SGLT2i,Active,Single,Randomized,Single Group,Industry,North America,HbA1c change,7.63,1.05,-0.399,0.004790756222398662,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71748672,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,143,16,2,SGLT2i,Placebo,Open Label,Randomized,Parallel,Industry,Asia,FPG change,7.82,1.0,-0.417,0.0004319337884886032,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT59005901,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,66,15,2,NovelSmallMolecule,StandardOfCare,Open Label,Randomized,Parallel,Academic,Asia,HbA1c change,9.44,1.42,-0.663,0.007455080250952206,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11107241,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,80,20,6,GLP-1RA,Placebo,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,9.68,0.92,-1.279,0.0,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT18610978,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,151,10,3,GLP-1RA,StandardOfCare,Double,Randomized,Parallel,Industry,Multi-Region,HbA1c change,9.11,0.75,-0.735,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT50888616,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,45,8,4,GLP-1RA,Placebo,Double,Randomized,Parallel,Academic,Europe,HbA1c change,9.32,1.3,-1.326,1.2905073639712938e-06,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT75032688,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,55,18,2,GLP-1RA,Active,Open Label,Non-Randomized,Crossover,Industry,Asia,FPG change,9.25,0.74,-0.942,3.330380415889067e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT84285955,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,90,9,5,NovelSmallMolecule,DoseComparison,Double,Randomized,Single Group,Government,Europe,HbA1c change,8.79,0.62,-1.027,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT48817142,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,9,5,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.63,1.33,-0.503,0.023862321095703742,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT36582311,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,87,21,5,Other,Active,Double,Randomized,Parallel,Industry,Europe,FPG change,8.78,1.14,-0.745,1.6071892221192208e-05,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT97147930,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,56,19,6,GLP-1RA,DoseComparison,Triple,Randomized,Parallel,Government,Other,CGM TIR,8.92,1.22,-1.002,1.3417468866627758e-05,Completed,Has Results,Not met / not primary / not significant,0
NCT51269326,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,110,8,2,TZD,Placebo,Double,Randomized,Parallel,Industry,Asia,Weight,7.88,0.99,-0.835,3.856671648705401e-10,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT38385074,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,93,12,6,DPP-4i,Placebo,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.91,0.75,-0.411,0.00019831590574148628,Terminated,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT49808270,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,127,11,3,DPP-4i,Active,Open Label,Randomized,Crossover,Academic,Asia,HbA1c change,9.42,0.8,-0.442,1.1468759858690447e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT11088248,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,27,4,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Industry,Other,FPG change,8.26,1.03,-0.114,0.41657837334027936,Recruiting,No Results Posted,Not met / not primary / not significant,0
NCT37173464,Phase 2 Other trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,109,21,5,Other,Placebo,Triple,Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.18,0.78,-0.644,1.2232265200751158e-09,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT56399900,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,52,13,5,NovelSmallMolecule,Placebo,Double,Randomized,Parallel,Government,Asia,FPG change,8.73,1.18,-0.853,0.00021948122452364327,Completed,Has Results,Not met / not primary / not significant,0
NCT92659769,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,124,19,2,SGLT2i,StandardOfCare,Double,Non-Randomized,Parallel,Other,Europe,HbA1c change,7.95,0.98,,,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT76440345,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,86,8,3,SGLT2i,Placebo,Double,Randomized,Parallel,Industry,Asia,CGM TIR,7.48,1.15,-0.534,0.002269201767747031,Terminated,No Results Posted,Not met / not primary / not significant,0
NCT80316462,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,92,12,2,TZD,Placebo,Double,Randomized,Crossover,Industry,Multi-Region,HbA1c change,9.2,1.14,-0.732,1.3099407636829596e-05,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT59041152,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,159,17,2,SGLT2i,StandardOfCare,Double,Non-Randomized,Parallel,Academic,Multi-Region,HbA1c change,8.08,1.2,-0.844,3.164483119988404e-10,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT19952956,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,72,19,2,NovelSmallMolecule,Placebo,Double,Randomized,Crossover,Industry,Multi-Region,HbA1c change,8.41,1.22,-0.758,0.00020489088110975384,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT45183382,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,183,15,5,Insulin,StandardOfCare,Triple,Randomized,Crossover,Industry,Europe,HbA1c change,7.97,1.01,-0.919,0.0,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT99733118,Phase 2 Insulin trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,191,17,2,Insulin,Placebo,Double,Randomized,Parallel,Industry,North America,FPG change,9.29,1.15,-1.294,0.0,Completed,Has Results,Not met / not primary / not significant,0
NCT13975390,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,140,16,5,NovelSmallMolecule,DoseComparison,Open Label,Randomized,Parallel,Industry,Asia,HbA1c change,9.0,1.16,-0.506,0.000260407142339214,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
NCT89128001,Phase 2 NovelSmallMolecule trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,64,15,3,NovelSmallMolecule,Active,Double,Randomized,Parallel,Industry,North America,HbA1c change,8.23,0.6,-0.466,1.0950564028111565e-05,Recruiting,No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT71604609,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,37,14,4,GLP-1RA,Placebo,Open Label,Non-Randomized,Parallel,Industry,North America,Weight,7.57,1.26,-0.447,0.12720317264069803,Completed,Has Results,Not met / not primary / not significant,0
NCT35551759,Phase 2 GLP-1RA trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,162,13,5,GLP-1RA,StandardOfCare,Open Label,Randomized,Parallel,Industry,Asia,CGM TIR,8.16,1.14,-0.819,9.176193138671351e-11,Completed,Has Results,Not met / not primary / not significant,0
NCT80018980,Phase 2 TZD trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,105,17,5,TZD,Placebo,Single,Randomized,Single Group,Industry,Asia,HbA1c change,8.8,1.24,-1.107,1.0361389524149445e-10,"Active, not recruiting",No Results Posted,"HbA1c improved (p<0.05, <=-0.30)",1
NCT85320691,Phase 2 DPP-4i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,71,18,3,DPP-4i,Placebo,Double,Randomized,Parallel,Other,Multi-Region,Composite,8.53,0.78,-0.821,3.3566860402345355e-10,"Active, not recruiting",No Results Posted,Not met / not primary / not significant,0
NCT13889718,Phase 2 SGLT2i trial in T2D (synthetic),Type 2 Diabetes Mellitus|Hyperglycemia,Phase 2,169,17,6,SGLT2i,Placebo,Open Label,Randomized,Single Group,Industry,Multi-Region,HbA1c change,8.48,1.02,-0.767,4.916067553040193e-12,Completed,Has Results,"HbA1c improved (p<0.05, <=-0.30)",1
